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Abbrevations 
 
AGE – Advanced Glycated End Products 
CAM – Cell adhesion molecule 
CS – Chondoritin sulfate 
CST - Chondroition sulfate transferase 
DM – Diabetes mellitus 
DS – Dermatan sulfate 
DST – Dermatan sulfate transferase 
ECM – Extra cellular matrix 
ER – Endoplasmatic reticulum 
ESRD – End stage renal disease 
EXT - Exostosin 
EXTL – EXT like gene product 
FGF – fibroblast growth factor 
FGFR – FGF receptor 
GAG – Glycosaminoglycan 
GalNAc – N-acetyl-galactosamine 
GalNAcT – GalNAc Transferase 
GFR – Glomerular filtration rate 
GlcA – Glucoronic acid 
GlcNAc – N-acetylated glucoronic acid 
GLUT – Glucose transporter 
HA - Hyaluronan 
HAS – Hyaluronan syntase 
HbA1c – Glycosylated heamoglobin A1c 
HexA – Hexuronic acid 
HS – Heparan sulfate 
HS4ST – HS-4-sulfotransferase 
HS6ST – HS-6-sulfotransferase 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ICAM – Intracellular CAM 
IL – Interleukin 
KS – Keratan sulfate 
LDL – Low density lipoprotein 
LPL – Lipoprotein lipase 
MMP – Matrix metalloproteinase 
NDST – glucosaminyl N-deacetylase / 
sulfo transferase 
PAPS - phosphoadenosine 5’-
phosphosulphate 
PCAM – Platelet CAM 
PDGF – Platelet derived growth factor 
PG – Proteoglycan 
PKC – Protein kinase C 
PSGL-1 – P-selectin-glycoprotein ligand-1 
SLRP – Small leucine-rich PG 
Sulf – sulfatase 
T1DM – Type 1 DM 
T2DM – Type 2 DM 
TGFβ – Transforming growth factor β 
TLR –Toll like receptor 
tPA – Tissue plasminogen activator 
UDP – Uridine diphosphate 
VCAM – Vascular CAM 
VEGF –Vascular endothelial growth factor 
VEGFR – VEGF Receptor 
vWF – von Willebrant factor 
WPB – Weibel palade body  
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1 Introduction 
During the past two decades, diabetes mellitus (DM) has emerged as a global 
epidemic, and we are experiencing an explosive increase in the number of people with this 
diagnose worldwide (1). This alarming development is partly brought about by behavioral- 
and lifestyle-related changes during the last decades. Easier access to high-energy foods, 
reduced physical activity and an increased prevalence of obesity are all important risk factors 
for DM. The increase in this disease can also be seen in relation to the achievements in public 
health services during the 20th century, with longer life expectancy owing to elimination of 
many of the infectious diseases. Thus, non-communicable diseases including diabetes, 
cardiovascular diseases and cancers, have now become the main public health challenge for 
the 21st century (2). DM is related to a range of complications, which reduce both the life 
quality and life expectancy of the victims, and as a result has significant economic 
implications both to individuals and for the society as a whole.  
1.1 Diabetes Mellitus (DM) 
DM is a group of chronic metabolic diseases characterized by hyperglycemia, 
resulting from defects in insulin and glucagon secretion, and insulin action. Insulin is a 
metabolic hormone produced by the β-cells of the pancreas. It enables glucose uptake in the 
cells primarily in the liver, adipose tissue and muscles, resulting in a stable blood glucose 
level under normal conditions. Both carbohydrate, protein and fat metabolism is affected by 
this anabolic hormone (3,4). Glucagon, on the other hand, is secreted by the pancreatic α-cells 
in response to decreased insulin levels, increasing the blood sugar levels by stimulating the 
release of hepatic glucose (5). The combined actions of insulin and glucagon are normally 
balancing euglycemia, but in diabetes this balance is disrupted, resulting in abnormal 
glucagon secretion involved in both hypoglycemia and hyperglycemia in diabetes (6,7). 
According to the World Health Organization (WHO) there was an estimated 153 
million people worldwide suffering from diabetes in 1980 (8). This number has already 
increased to 366 million in 2011 (9) and is expected to reach 552 million in 2030 (4). 
Consequently, the mortality rate due to DM is projected to double from 1.2 million in 2005 to 
2.4 million in 2030.  The two main forms of DM are type 1 (T1DM) and type 2 (T2DM) (10). 
T2DM is the dominating and most rapidly increasing form of diabetes, accounting for 90 % of 
the cases, and resulting in both morbidity and mortality worldwide. The incidence of T1DM 
in children younger than 15 years was increasing up until 2005 (11), a trend which is now 
stopped (EASD 2012). Still, however, T1DM is the most common chronic disease of children 
in Europe. A large portion of the international diabetic epidemic is seen in developing 
countries. However, also in Norway as many as 135,000 people use diabetic medication today 
(12).  In some women, pregnancy provokes hyperglycemia, and  gestational diabetes is 
affecting 3-10 % of pregnancies (13). As with diabetes in pregnancy in general, these 
offspring are at risk for birth complications as well as increased risk of developing obesity 
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and T2DM, and the mothers have increased risk of developing T2DM in the years following 
childbirth (14). 
The current WHO diagnostic criteria for diabetes are fasting plasma glucose ≥ 7.0 
mmol/l or 2 hours plasma glucose ≥ 11.1mmol/l (15). New WHO diagnostic criteria from 
January 2011 includes the use of glycosylated heamoglobin A1c (HbA1c) ≥ 6.5 %,  reflecting 
the long-term blood glucose levels in diagnosing diabetes (16). These criteria were accepted 
also by the Norwegian Directorate of Health this fall. 
Even though both T1DM and T2DM primarily are the results of impaired insulin 
action, these are two very different diseases. T1DM is an autoimmune disease, considered to 
be caused by a combination of genetic predisposition and environmental factors, such as viral 
infection (17). A recent study suggests a role for intestinal bacteria entering the pancreatic 
duct as a trigger for T1DM (18). Due to autoimmune destruction of the insulin-producing β-
cells of the pancreas, the body is not able to produce insulin, which must be supplied by 
injection (10). In T2DM on the other hand, insulin is still produced, but either the insulin 
production is insufficient or the sensitivity for the hormone is too low, referred to as insulin 
resistance (10). Additionally, hyperglucaconemi is a result of this reduction in insulin 
secretion (6). The development of T2DM is closely related to lifestyle, such as intake of high-
energy food rich in simple carbohydrates and saturated fat, as well as a sedentary lifestyle, 
culminating in excess body weight (1,2). T2DM can be managed with diet, physical activity, 
tablets increasing the sensitivity or secretion of insulin or reducing glucagon release, and in 
severe cases also insulin injections. Alarmingly, the T2DM patients are outnumbered by those 
experiencing the metabolic syndrome. This condition is recognized by the combination of risk 
factors such as insulin resistance, abdominal obesity and hypertension, associated with 
increased risk of developing T2DM and cardio-vascular disease (10). As with T2DM, the 
metabolic syndrome is a lifestyle related disease, associated with physical inactivity, 
inappropriate diet and overweight.  
Initial symptoms of T1DM, are frequent urination, and increased thirst and hunger (4). 
In DM, the high blood glucose concentration results in excess urination, which in turn results 
in increased thirst. Hunger, and in some cases weight loss, is caused by the deprivation of 
glucose as an energy source, as it cannot enter the cells. More acute life-threatening 
consequences of DM include diabetic ketoacidosis and non-ketotic hyperosmolar syndrome 
(19). In the absence of insulin, fatty acids are released from the adipose tissue and used as an 
energy source. The resulting ketone bodies will reduce the pH of the blood, potentially 
resulting in ketoacidosis in T1DM. In T2DM hyperglycemia-induced osmotic diuresis could 
cause severe dehydration, resulting in the non-ketotic hyperosmolar syndrome. Finally, in the 
long term multiple vascular complications occur, resulting in organ and tissue damage in 
approximately one third to one half of diabetics (20). Microvascular complications include 
diabetic retinopathy and nephropathy, potentially resulting in blindness and kidney failure, as 
well as neuropathy which outcome depends on the nerves affected. Foot ulcers and 
amputations are often results of longstanding neuropathy in diabetes. Macrovascular 
complications include atherosclerosis and can lead to ischemic heart disease, peripheral 
vascular disease, and cerebrovascular disease (21).  
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While T1DM is an autoimmune disease, T2DM is regarded as an autoinflammatory 
disease (22). Components of the immune system are altered in T2DM, suggesting a role of 
inflammation in the pathogenesis of T2DM. The obesity often observed in T2DM is linked to 
elevated levels of plasma free fatty acids (23), and excessive levels of glucose and free fatty 
acids will stress the pancreatic islets and insulin-sensitive tissues such as adipose tissue and 
muscle. This will lead to local production and release of cytokines and chemokines such as 
Interleukin (IL)-1β. These are also released to the circulation, affecting other tissues as well 
(22,24). This will in turn lead to endothelial dysfunction, inflammation and atherosclerosis, 
and ultimately resulting in the micro- and macro vascular complications mentioned above. 
Thus, prolonged hyperglycemia is a crucial factor in the development of the diabetic 
complications, especially microvascular complications (21,25-27), and therefore strict blood 
glucose control is essential in managing this disease by preventing both acute and long-term 
complications. 
-- 
 
 
Fig. 1. Illustration of the structure of the vessel wall in arteries (a), veins (b) and capillaries (c).  The 
endothelium is resting on the basement membrane  present in all the different parts of the vasculature. 
Taken from [http://faculty.spokanefalls.edu/InetShare/AutoWebs/GaryB/AP%20243/Unit%203/ 
Blood%20Vessels%20and%20Hemodynamics_files/frame.htm#slide0002.htm]28.07.201
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1.2 The endothelium 
DM is hallmarked by vascular complications brought about by dysfunction of the 
endothelium, vascular inflammation and atherosclerosis. The endothelium is forming the 
inner lining of the vasculature, and is the prime organ to be exposed to hyperglycemic 
conditions. Endothelial cells are highly specialized, multifunctional squamous epithelial cells, 
which predominately express the insulin-insensitive glucose transporter GLUT-1 (28,29). 
Consequently, intracellular glucose concentrations are reflected by the extracellular glucose 
levels, making endothelial cells especially sensitive to hyperglycemia. 
 
1.2.1 Normal function of the endothelium 
The endothelium is composed of a monolayer of endothelial cells resting on a 
basement membrane, forming the inner lining of all blood vessels, as illustrated in Fig. 1. The 
human body contains approximately 1013 endothelial cells of a total weight of almost 1 kg and 
covering a surface area of 4-7000 m2, thus constituting a large and important organ (30,31). In 
separating the blood from the underlying tissue, the endothelium forms a selective 
permeability barrier controlling the transfer of small and large molecules into the vessel wall. 
Both the monolayer of endothelial cells, as well as the underlying extracellular matrix (ECM), 
is important in controlling the vascular permeability (32). The endothelial cells synthesize 
constituents of the underlying (basolateral) basement mebrane and ECM, along with enzymes 
participating in the remodeling of this matrix, such as matrix metalloproteinases (MMPs), 
heparinases and sulfatases as well as ADAMs and serine proteases. Major components of the 
basement membrane are heparansulfate (HS) proteoglycans (PGs) such as perlecan and 
collagen type XVIII, as well as laminin, nidogen-1 (entactin) and collagen type IV.  Important 
ECM components are both chondroitin sulfate (CS) / Dermatan sulfate (DS) - and HSPGs, 
hyaluronan (HA), collagen and elastin fibers and fibronectin, produced both by endothelial 
and other resident cells such as fibroblasts and smooth muscle cells. Additionally, the luminal, 
or apical, side of the endothelium is covered by the endothelial glycocalyx (33,34); a network 
of membrane-bound PGs, HA and glycoproteins. Electron microscopy images of this 
structure are shown in Fig. 2. The glycocalyx is also important for the endothelial 
permeability and leukocyte adhesion (35), and has a significant barrier function in the 
glomerular endothelium  (36).  
Regulation of the permeability trough the endothelial cell layer is obtained through 
control of both transcellular and paracellular transport (32,37,38). Endothelial permeability to 
plasma proteins and liquid is increased in inflammation due to effect on these junctions. In 
addition to promoting cell-cell adhesion, junctions might also transfer intracellular signals that 
regulate contact-induced inhibition of cell growth, apoptosis, gene expression and new vessel 
formation (39). This is reflected in the different behavior of confluent and sparse cell cultures. 
Sparse cultures are in a proliferative state with active growth and motility. The endothelial 
cells lining the blood vessels on the other hand, are confluent. These cells are typically 
“quiescent” in the sense that they are not actively proliferating, and the average life span of an 
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endothelial cell is more than 1 year (40-42). The interendothelial junctions in the dense cell-
layer contribute to this quiescent phenotype by transmitting signals within the cells, changing 
their gene expression. When they reach confluence and their junctions become more 
organized, they lose the ability to respond to growth factors, and they switch to a resting 
condition.  Sparse cells, which lack cell-cell junctions, are unable to transduce such signals 
(39). This can be exemplified by the response of endothelial cells to stimuli with transforming 
growth factor (TGF) β1, which is dependent both on cell shape, proliferative state and the 
source of the cells (43,44). The contact-inhibition of dense cell-cultures will promote 
quiescence (45).  
 
 
 
Fig. 2. Electron microscopy image of the endothelial glycocalyx in a coronary capillary, taken from 
(34).  
 
The endothelium is regarded as a metabolically active organ having impact on a wide 
range of processes other than in the biosynthesis of ECM components. These include the 
immune response, coagulation, growth regulation and modulation of blood flow and blood 
vessel tone (30,31,38). This is achieved by the production of a wide range of molecules, 
summarized in Fig. 3, taken from (31).  
Endothelial proteins are secreted both trough regulated and constitutive pathways. 
Weibel Palade Bodies (WPB) are the best characterized secretory vesicles in endothelial cell 
(46). These rod-shaped structures are unique to endothelial cells, and represent the storage 
organelle for von Willebrand factor (vWF), a glycoprotein involved in hemostasis (31). 
Recently the WPBs were shown to be a dynamic storage pool for several other components as 
well, depending on stimuli such as inflammatory conditions (39,47). In human umbilical vein 
endothelial cells (HUVEC), IL-8 is found in WPB, but only after IL-1β stimulation, and tissue 
plasminogen activator (tPA) is found only in part of the WPBs (47). Furthermore, separate 
tPA storage vesicles have been identified (48). Recently, a novel chemokine-containing 
compartment named the type 2 endothelial granule for regulated secretion, was also described 
(49,50), containing CXCL1 (GROα) and CCL2 (MCP-1).  
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Fig. 3. Illustration of the main classed and most important  molecules the endothelial cell is capable of 
producing, taken from (31).  
1.2.2 Endothelial dysfunction and atherosclerosis 
Under normal conditions the endothelium participate in regulating blood clotting, 
assisting the body's immune response, controlling fluid volume and the amount of electrolytes 
that pass from the blood into the tissues, affecting dilation or constriction of blood vessels. 
However, in endothelial dysfunction, the ability to perform one or more of these functions is 
affected. In diabetes, dysfunction of the vascular endothelium is regarded an important factor 
in the pathogenesis of both diabetic micro- and macroangiopathy (51). Endothelial 
dysfunction plays a major role in the development of atherosclerosis, contributing to diabetic 
macrovascular complications.  
The effect of hyperglycemia on the microvasculature is mediated through increased 
flux trough several metabolic pathways. These include the hexosamine-, polyol-, PKC- and 
the AGE (Advanced glycated end products) -pathways (52,53). High intracellular glucose 
concentrations will increase flux through the glycolysis and ultimately lead to an 
accumulation of the upstream glucose-metabolites, and increase the flux through all the above 
mentioned pathways. The glucose donors uridine diphosphate (UDP)-N-acetyl-glucosamine 
(GlcNAc) and UDP-N-acetyl-glucosamine (UDP-GalNAc) are intermediates of the 
hexosamine pathway. Such altered substrate-availability for glycosaminoglycan (GAG) 
synthesis has the potential to affect PG expression, as well as the modifications of other 
glycoproteins. In addition, increased flux trough the hexosamine pathway will increase the O-
GlcNAc-modifications of a wide range of proteins. This is a process similar to 
phosphorylation, affecting gene expression and signaling, and contributing the glucose-
toxicity of diabetes (54). In hyperglycemia, a series of proteins are also modified trough 
glycation leading to the generation of AGE and vascular damage. AGE levels are increased 
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both in the circulation and the tissue of diabetics (55). Hyperglycemia will also increase 
diacylglycerol content and activate PKC, having a number of pathogenic consequences on the 
vasculature. Furthermore, increased flux through the polyol pathway is especially important 
in the development of diabetic cataract.  
Atherosclerosis is a chronic inflammatory disease affecting large - and medium-sized 
arteries throughout the cardiovascular system. One major feature is artery wall thickening as a 
result of accumulation of cholesterol, which may eventually result in restriction of blood 
supply to the tissues (stenosis) and potentially thrombus rupture which may in turn lead to 
ischemia. Inflammation plays a key role both in the initiation and throughout this process.  
The rapid recruitment of leukocytes from the blood to the site of inflammation is an essential 
feature of the inflammatory response. PGs have important roles in this multi-step process, 
which is accelerated in endothelial dysfunction. The overview of these steps and the 
involvement of PGs are illustrated in Fig. 4.  
 
 
 
Fig.4. Leukocyte recruitment from the vasculature into surrounding tissue is a multistep process 
involving leukocyte rolling, firm adhesion, spreading and extravasation. Platelet (P)- and endothelial 
(E)-selectin on the activated endothelium interact with ligands such as PSGL-1 (P-selectin 
glycoprotein ligand-1) on the leukocyte. Rolling is further stabilized by interactions between 
endothelial HSPG and L-selectin. Chemokines bound to HSPGs on endothelial cells are presented to 
leukocytes and further activates leukocyte-integrins, resulting in a more stable adhesion with ICAM 
(intracellular CAM) and VCAM (vascular CAM). Once arrested on the endothelial surface, the 
activated leukocytes traverse the endothelium and interact with chemokines presented by basement 
membrane HSPGs. The basement membrane is passed by degradation by enzymes such as MMPs and 
heparanase, secreted both by the leukocytes, endothelial cells and platelets (56-58). The figure is 
taken from (59).  
 
Fatty streaks, the initial atherosclerotic lesions or plaques, are developed when the 
monocytes that migrate into the intima mature into macrophages. Macrophages express 
scavenger receptors, enabling them to engulf oxidized low-density lipoprotein (LDL) and 
form foam cells. Cell surface PGs play a role in cellular uptake of lipoproteins (60) and 
basementmembrane PG Collagen XVIII is suggested to bind lipoprotein lipase (LPL) and 
facilitate its transport to the endothelial surface (61). The retention hypothesis of 
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atherosclerotic development first outlined in 1995 (62,63), focus on PGs mediating 
lipoprotein retention as a critical step in the initiation of atherosclerotic development. 
Deposited PGs such as biglycan in the intima may retain atherogenic lipoproteins such as 
LDL, contributing to fatty streak development. Formation of an advanced lesion or 
atherosclerotic plaque occurs as a necrotic core of leukocytes and lipids and a fibrous cap 
evolve in the fatty streaks, leading to the formation of the arterial plaque.   
T2DM is regarded an inflammatory disease, with increased levels of pro-inflammatory 
cytokines including IL-6, TNFα, MCP-1 and IL-1β. Elevated IL-1β levels are predictive of 
T2DM (64) and IL-1 signals via IL-1 receptor type 1 (IL-1R1) and IL-1RAP /IL-1, also 
expressed by ECs. A number of inflammatory cytokines are also involved and elevated in 
T1DM (65), including IL-1 (66). 
1.2.3 Human umbilical vein endothelial cells - HUVEC 
HUVEC are cells derived from the endothelium of veins from the umbilical cord (Fig. 
5). Umbilical veins has been a widely used source of primary human endothelial cells ever 
since they were first isolated and cultured by Jaffe et al in 1973 (67). In placental mammals, 
the umbilical cord is the connecting cord from the fetus to the placenta. The umbilical cord is 
physiologically and genetically part of the fetus and contains two arteries and one vein. The 
umbilical vein supplies the fetus with oxygenated, nutrient-rich blood from the placenta. 
Conversely, the fetal heart pumps deoxygenated, nutrient-depleted blood through the 
umbilical arteries back to the placenta. It is unusual for a vein to carry oxygenated blood and 
for arteries to carry deoxygenated blood. However, these veins are exposed to environment 
usually describing arteries. 
 
 
 
Fig. 5. A cross-sectional view of the umbilical 
cord reveals one umbilical vein and two 
umbilical arteries, taken from 
[http://homepages.cae.wisc.edu/~bme300/umbi
lical_f07/]. 
These cells were successfully grown on plastic surfaces or gelatin-coated glass, and if 
grown on permeable filters, they become polarized with an apical and a basolateral membrane 
separated by tight junctions, more closely resembling the in vivo situation of the endothelium. 
Advantage can be taken of such a system when studying the polarized sorting of secretory 
molecules. HUVEC express ECM components like collagen IV in addition to HSPGs like 
perlecan, agrin and collagen XVIII and the CSPGs decorin, biglycan, and versican as well as 
glycocalyx components syndecans, and serglycin important for the intracellular storage and 
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sorting of cytokines. HUVEC are also able to express several proinflammatory cytokines such 
as IL-1β, IL-6, IL-8 and TNFα as well as Intracellular adhesion molecule-1 (ICAM-1), 
platelet-CAM-1 (PCAM-1), P-selectin, E-selectin, and VE-cadherin, corresponding to 
molecules expressed by endothelial cells in vivo (68).  
1.3 Proteoglycans and glycosaminoglycans 
The endothelium is a main target of the diabetic complications (51), and PGs 
expressed by these cells have been implicated in the development of diabetic complications 
(56,69). PGs are molecules consisting of a protein core to which extended linear carbohydrate 
side chains are covalently attached. Based on the composition if these GAG chains, the PGs 
belong to the HS, CS, DS or keratan sulfates (KS) class. The anticoagulant heparin is a highly 
modified form of HS produced by mast cells and attached to the serglycin core protein. 
Hyaluronan on the other hand, is synthesized as a free GAG- chain with no attachment to a 
core protein. These GAG chains are highly polyanionic structures, providing the PGs with 
unique qualities.  
 
 
 
Fig.6. The structure of the repeating disaccharide region of hyaluronan (HA), chondroitin sulfate 
(CS), dermatan sulfate (DS), heparan sulfate (HS)/heparin (Hep), and keratan sulfate (KS) is shown. 
Possible sulfation positions are given and an asterisk in the structure of HS/Hep indicates that the C5 
position of the uronic acid residue may be epimerized. The picture is taken from 
[http://jcggdb.jp/GlycoPOD/protocolShow.action?nodeId=t15]28.07.2012. 
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1.3.1  Structure 
The GAG chains are linear polymers of repeating disaccharide units covalently O-
linked to serine on the core protein. These disaccharide units consist of alternating hexuronic 
acids (HexA) and hexosamines. In HS and CS/DS, the HexA is either glucoronic acid (GlcA) 
or iduronic acid (IdoA), and the hexosamine is GlcNAc or GalNAc. Thus, depending on the 
structure of the repeating disaccharide, the GAGs are divided into HS/heparin (GlcA/IdoA + 
GlcNAc), CS (GlcA + GalNAc), DS (IdoA + GalNAc), KS (Gal + GlcNAc) and hyaluronan 
(GlcA + GlcNAc) (70,71). These structures are illustrated in Fig. 6. Added to these basic 
structures is yet another level of complexity, brought about by numerous biosynthetic 
modifications that can occur at discrete positions within a chain, also indicated in Fig. 6. 
These modifications include N-deacetylation, N- and O-sulfation and epimerization. Not all 
potential sugars or positions will be modified, thus the extent of modification will vary along 
the chain, creating structurally different domains. In HS, these domains include the unsulfated 
N-acetylated (NA) - areas, N-sulfated (NS) areas with high degree of modification, and the 
NA/NS areas with varying degree of modification usually flanking the NS-areas (71,72).  
 
The PGs are a very heterogeneous group of molecules, both in size, structure, number 
of GAG chains, expression levels and function. A range of very different proteins carry GAG-
chains, creating yet another degree of diversity. Also, the GAGs are subjected to various 
degrees of posttranslational modifications including epimerization, deacetylation and 
sulfation. Finally, this structure could be subjected to enzymatic post-translational 
modifications by heparitinases and sulfatases. The functions of the PGs rely on the core 
proteins or the GAG chains attached. PGs can also be classified according to structural feature 
or specific functions of the protein cores. However, based on their localization, they are often 
referred to as either intracellular, cell-surface or extracellular PGs.  Finally, “part-time PGs” 
also exists. These are proteins that may exist and function either with or without a GAG chain 
attached.  
The diversity of the PG structure and localization is illustrated in Fig. 7. 
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Fig. 7. Illustration of the diversity of PG structure and localization, reflecting the variety of their 
functions. Taken from (73).  
 
Cell surface PGs.  
 
Several cellular processes involving molecular interactions at the cell surface, such as 
cell-matrix, cell-cell and ligand-receptor interactions, are likely to involve PGs. Two major 
families of cell surface PGs have been identified: the syndecans and the glypicans. In 
endothelium, these are found both at the basolateral surface, promoting adhesion to the ECM, 
as well as at the luminal or apical side as part of the glycocalyx, and enzymatically shed both 
into the bloodstream and into the ECM.  
The glypicans consists of six members attached to the cell surface trough GPI-anchors 
(74,75). The four syndecans on the other hand are a family of type 1 transmembrane proteins 
with intracellular cytoplasm domain involved in intracellular signalling (76). The syndecans 
typically have 3-5 HS chains attached, although CS may also be present on syndecan-1 and -
3. Syndecan-1 is common in epithelium and plasma cells, syndecan-2 is present in many 
mesenchymal cell types but also in developing neural tissue, and is the dominating form in 
endothelium. Syndecan-3 is enriched in neural tissue and in the developing musculoskeletal 
system. In contrast, syndecan-4 is widely distributed in many cell types (76). Through the 
actions of their GAG-chains they act as co-receptors, interacting with matrix components and 
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growth factors which in turn promote intracellular signaling cascades (77).  Also, syndecans 
may be proteolyticaly cleaved by enzymes such as MMPs, in a process known as shedding. 
This is an important regulatory mechanism, rapidly changing surface receptor dynamics and 
generating soluble ectodomains (78). Different MMPs has different affinities for different 
syndecans, and are inhibited by the actions of TIMPs. It has been reported that syndecan-1 in 
the circulation is increased in T1DM pasients with microalbuminuri compared to those 
without (79).  
 
ECM PGs.  
 
Connective tissue is generally composed of a network of proteins such as collagens, 
glycoproteins such as fibronectin, HA and PGs. The properties and architecture of a tissue 
depend on which components are secreted locally to the matrix by the residing cells. The PG 
composition will vary between different tissues, depending on the functions of the PGs. Due 
to the striking polyanionicity of the GAG chains, PGs have the ability to form gels even at 
low concentrations, giving them important functions as shock absorbers, such as in cartilage. 
Importantly, although essential for structure and shock absorption, the PGs also have 
important roles in several other cellular functions. PGs are especially abundant in bone and 
cartilage, and matrix PGs are particularly well studied in cartilage where they constitute over 
90 % of the dry weight of the tissue. The most common cartilage PG is aggrecan, named so 
because it forms large aggregates with HA.  
In vascular tissue, important matrix-PGs are CS/DSPG versican, small leucine rich PGs 
(SLRPs) decorin and biglycan along with the large basement membrane HSPGs perlecan, 
collagen XVIII and agrin.  
Versican belongs to the family of the large aggregating CSPGs. It has multiple 
functions as it interact with many ECM components such as HA, tenascin, fibulins, fibrillin 
and fibronectin as well as cell surface proteins such as selectins, CD44, integrin and EGFR 
(epidermal growth factor receptor) and P-selectin-glycoprotein ligand-1 (PSGL-1). The 
multiple functions of versican can be explained by these varying binding partners and 
multiple isoforms of this PG (80).  
The small leucine-rich PGs (SLRPs) are named for their small size (up to 42 kD) and 
the leucine-rich repeats of the protein core. CS/DS PGs Decorin and biglycan, belonging to 
the Class I of SLRPs, are the most extensively studied of these molecules. Decorin is 
substituted with one, and biglycan with two, CS/DS chains, as well as three and two N-linked 
oligosaccharides respectively. The leucine-rich repeats of the protein core, as well as the GAG 
side chain(s), allow for a wide range of matrix- matrix and matrix-cell interactions, and as 
ECM components they are important in matrix assembly (81). Illustrating this point, decorin 
is so named due to its ability to “decorate” collagen fibers in the ECM.  However, other roles 
are emerging for soluble, no-matrix bound fragments of decorin and biglycan. They are 
secreted, or liberated from the matrix by the action of MMPs, and they have the ability to 
functions as receptor ligands influencing cell behavior (82,83). Thus, these PGs have 
functions related to structure, proliferation, differentiation, survival, adhesion, migration and 
the inflammatory response. Decorin has anti-fibrotic effects trough interaction with TGFβ 
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signaling, and is involved in the pathogenesis of renal fibrosis (83). Decorin is also able to 
bind and inhibit CCN2 (connective tissue growth factor), essential for fibrosis (84). As for 
their roles in inflammation, decorin is inversely related to atherosclerosis (85), while soluble 
biglycan act as a pro-inflammatory signaling molecule (82). 
Another small PG affected by inflammation is DSPG endocan. Endocan is 
synthesized in moderate amounts by endothelial cells, mainly in kidney and lung, but the 
expression is markedly increased in the presence of pro-inflammatory and pro-angiogenic 
molecules, and is regarded a marker of endothelial dysfunction (86,87) and is suggested to be 
a potential cancer marker (88).   
The basement membrane is a specialized sheet like form of ECM that supports the 
endothelium, epithelium and several other cell types. It is composed of four major molecules; 
laminin, type IV collagen, nidogen and PGs. The subendothelial basement membrane has 
been shown to be dominated by HSPGs perlecan, collagen XVIII and agrin (89,90), although 
extensive studies on the CSPGs in this specialized ECM has not been performed. The HSPG 
composition of the basement membrane differs between various tissues; e.g. in glomerular 
basement membrane agrin is the dominating HSPG (91), while perlecan dominates in many 
other tissues.  
Perlecan is named from the appearance of its protein core as a string of pearls. It is a 
ubiquitous macromolecule predominately expressed in basement membranes, as well as ECM 
in general. The ~470 kDa protein core consists of five domains labeled I-V. Adding the 
numerous O-linked oligosaccharides and as many as four HS chains, the molecular weight for 
intact perlecan can reach 800 kDa. The various modules of the perlecan protein core and its 
HS chains can take part in a large number of molecular interactions. The binding partners 
include proteins of the basement membrane and ECM, cell surface proteins, and growth 
factors such as fibroblastic growth factor (FGF), vascular endothelial growth factor (VEGF) 
and PDGF (platelet derived growth factor) (90,92).  Perlecan is synthesized by both vascular 
endothelial and smooth muscle cells and deposited in the ECM, but can also be associated 
with the cell surface. Moreover, perlecan is also expressed in avascular tissues such as 
cartilage. Not surprisingly, perlecan is involved in a number of pathological processes, 
including atherosclerosis. Endorepellin is the 85 kDa C-terminal domain V of the perlecan 
protein core, which can be cleaved by the action of MMPs. Similar to the C-terminal of 
collagen XVIII, endostatin, and tumstatin of the part-time PG collagen IV, endorepellin is 
found to inhibit angiogenesis (93). These fragments of basment membrane PGs modulate 
endothelial cells trough interactions with integrins.  
Also abundant in basement membranes, of e.g. blood vessels, is HSPG Collagen 
XVIII (94) which is expressed in three variants, of which the shorter one is found in most 
vascular and epithelial basement membrane structures. In mouse kidney, lack of the long 
isoforms affects kidney podocytes, whereas the short form is needed in the proximal tubular 
basement membrane (95). Lipoprotein lipase presentation on the luminal side of endothelium 
depends on collagen XVIII (61) implicating this molecule in triglyceride metabolism. The C-
terminal fragment of collagen XVIII, endostatin, is an inhibitor of angiogenesis and tumor 
growth by restricting endothelial cell proliferation and migration (96).  
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More abundant in the glomerular basement membrane is HSPG agrin, expressed in 
several isoforms in several tissues and originally known for its functions in the synaptic 
basement membrane (89,91). In the human glomerular basement membrane, agrin has 
important functions in the charge barrier (89,91,97).  
 
Intracellular PGs.  
 
Serglycin is the most prominent intracellular PG. Apart from some reports e.g. on the 
presence of syndecans in the cytoplasm and nucleus (98), serglycin is the PG with most 
documented intracellular functions. This molecule has its name from the extensive stretch of 
ser-gly-repeats present in the approximately 15 kDa protein core, representing the attachment 
sites for the GAG chains. As a result of the close proximity of these sites, serglycin is densely 
substituted with GAGs, providing its characteristic resistance to proteolytic cleavage 
(99,100). 
 Originally regarded as a PG of the hematopoietic cells, this molecule is most 
extensively studied in these cells (101). However, serglycin was later found to be expressed 
by several other cell types (102), including ECs (103,104), chondrocytes (105), smooth 
muscle cells (106) and in tumors (107).  
Studies from connective tissue mast cells show that serglycin in these cells is 
substituted with the oversulfated form of HS, heparin. In mucosal mast cells however, as well 
as other hematopoietic cells, serglycin carries CS-chains, mostly of the CS-4S or CS-4,6S 
form, sulfated at the 4-O or 4 and 6-O position of GalNAc. Serglycin carrying heparin chains 
have so far only been detected in connective tissue mast cells. Serglycin containing HS has 
been identified (108), as well as hybrids carrying both heparin and CS (102). Finally, the size 
and number of GAG chains varies, not only between cell types, but also as a response to 
stimuli. All of these factors accentuates the dependence of serglycin structure on the tissue or 
cells type in which it is expressed.  
Being most highly expressed by mast cells, the functions of serglycin is thoroughly 
studied in these cells. Lessons from the serglycin knockout mouse demonstrate that serglycin 
has a key role in the granular storage of several mast cell-specific proteases through 
electrostatic interactions to the sulfated GAG chains (109). Knockout of the serglycin protein 
results in several similar phenotypes as those in glucosaminyl N-deacetylase /N-
sulfotransferase (NDST)-2 knockout (110), supporting the role of the GAG-chains (heparin) 
in this process. Trough use of the serglycin knock-out mouse it has been established that both 
leukocytes (109), platelets (111), macrophages (108) and cytolytic T-lyphocytes (112) are 
affected by the absence of this PG.  
Thus, serglycin is important in granule formation, destined for storage or constitutive 
secretion, also induced by e.g. inflammatory stimuli. The functions of secreted serglycin are 
intriguing. Serglycin is implicated in the secretion of several compounds including proteases, 
but also cytokines and chemokines (113). Following secretion, the serglycin complexes can 
dissociate due to the increasing pH. Alternatively, depending on the strength of the 
interactions, the partner molecules may remain in complex with serglycin. This may have 
several functional consequences, including promotion of proteolytic protection, and 
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facilitation of chemokine or cytokine transport and presentation or protease interaction with 
substrate. Serglycin is also a possible scavenger, sequestering inflammatory compounds such 
as GAG-binding chemokines (102,113,114). 
Thus, the exact function and structure of serglycin varies between these different cell types; 
hence the description of serglycin as “a structural and functional chameleon” (102).  
1.3.2 Biosynthesis 
The protein component of the PGs is synthesized trough the classical pathway on 
ribosomes and translocated into the lumen of the rough endoplasmic reticulum (ER). 
Glycosylation of the PG occurs in the Golgi apparatus through multiple enzymatic steps. First 
a specific tetrasaccharide link side chain is attached to a serine on the core protein to serve as 
a primer for the polysaccharide growth initiation. Then sugars are added one at a time by 
specific glycosyl transferases. The completed PGs are then exported in secretory vesicles to 
their destinations or into storage granules (71). 
 
GAG chain initiation 
 
Following translation, the core protein is translocated into the ER where modifications 
such as N-glycosylation and addition of GPI-anchors are acquired. The building blocks for 
GAG synthesis, sugars and sulfate, are activated by nucleotide conversion in the cytosol into 
UDP-sugars and 3’-phosphoadenosine 5’-phosphosulfate (PAPS), respectively. These are 
translocated into the ER and Golgi lumen by specific transporters. GAG chain synthesis is 
initiated trough sequential addition of monosaccharides onto a tetrasaccharide link: xylose – 
galactose – galactose – GlcA. This linker serves as primer both for HS/heparin and CS/DS 
chain polymerization, taking place either in a pre-Golgi compartment or in the Golgi 
apparatus (71,115,116).  
Whether the first sugar added to the linker is GlcNAc or GalNAc will commit the 
chain to either HS/heparin or CS/DS synthesis, respectively. This first addition to the primary 
linker could be determined by several factors, such as the amino acid sequence flanking the 
serine residue on the core protein, the access of UDP sugars or the presence of GAG-
synthesizing enzymes. Modifications of the linker region including phosphorylation of the 
xylose residue, sulfation of the two galactoses and epimerization might also be important. No 
sulfation has yet been demonstrated for HS/heparin linker regions, supporting the hypothesis 
that sulfation of the linker is characteristic for CS/DS chains (71,117). The synthesis of the 
linker is a common pathway for HS/heparin and CS/DS synthesis. However, the elongation 
and modification of these are catalyzed by different sets of enzymes, and these reactions also 
take place at different subdomains of the Golgi apparatus. The enzymes necessary for HSPG 
synthesis are located in the cis,- medial,- and trans Golgi cisternae, while CSPG enzymes are 
found in the trans-Golgi network (71). 
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Synthesis of HS / heparin 
 
HS chain polymerization is initiated by the addition of GlcNAc by EXT -like gene 
product 2 (EXTL2) or EXTL3, members of the exostosin (EXT) family (118). The HS chains 
are further elongated by the co-polymerase EXT1/2, a hetero-complex of EXT1 and EXT2 
(119,120), both possessing dual GlcA/GlcNAc-transferase activity, but with higher activities 
when in complex (121). HS chains are elongated by the alternating addition of GlcA and 
GlcNAc residues to the non-reducing end of the chain. The growing chain is modified at 
various positions including deacetylation and N-sulfation of GlcNAc, epimerization of GlcA 
into IdoA and O-sulfation at various positions of the disaccharides (69).These steps are 
illustrated in Fig. 8.  
The modification of HS are initiated by N-deacetylation and subsequent N-sulfation of 
selected GlcNAc residues, creating GlcNS. The two reactions are carried out by a bi-
functional enzyme, the NDST. N-sulfation is unique to HS/heparin and do not occur in the 
other GAGs. In mammals four NDSTs have been identified; NDST1 and NDST2 are 
expressed in most tissues, while NDST3 and NDST4 are expressed during embryonic 
development (70). HS chains have a domain structure in which sulfated domains (NS-
domains) alternate with unsulfated regions (NA-domains). The N-sulfation carried out by 
NDST is required for further modification of the HS chain. Thus, NDST will create the 
overall design of the HS chain. Following N-sulfation, C5-epimerization of GlcA into IdoA 
by C5 GlcA-epimerase occurs. Then HS chains are selectively sulfated at the 2-O position of 
the uronic acid and the 6-O and 3-O position of GlcNS residues. 2-O-sulfation is carried out 
by the HS 2-O-sulfortransferase (HS2ST) at the C2 position of GlcA or, preferably, IdoA. 
The transfer of sulfate from the sulfate donor PAPS to position 6 of GlcNAc and GlcS 
residues is catalyzed by three different HS 6-O-sulfotransferases (HS6ST). The 3-O-sulfation 
catalyzed by HS3ST of GlcNAc residues is the rarest modification, creating the characteristic 
modifications of the oversulfated heparin. NDST1, EXT1 and EXT2 is suggested to operate 
in large complexes called GAGosomes, possibly also in concert with sulfotransferases (122-
124). Thus, GAGosomes of different compositions might result in different HS modification 
patterns (125).  
After synthesis and extensive modification, the HSPG are transported from the Golgi 
to the ECM or the cell surface, where they might be subjected to additional modifications by 
the action of sulfatases (Sulfs), sheddases or heparanase. Sulf1 and Sulf2 are cell-surface 
associated sulfatases, able to remove 6-O-sulfate from GlcN-residues in HS (126). In several 
organisms, two different Sulfs has been identified, the human forms being designated hSulf1 
and hSulf2. Both are believed to exert the same substrate specificity (127). However, recent 
findings indicate that Sulf1 and Sulf2 differentially contribute to the generation of organ-
specific sulfation patterns of HS (128). Furthermore, HS structure could be significantly 
modulated by the action of heparanase, an endo-β(1,4)-glucoronidase, cleaving the HS chains 
at specific sites (129). Heparanase is upregulated in a number of inflammatory conditions 
(58), and increased in T2DM patients (130). Finally, sheddases such as MMPs cleaving the 
extracellular core protein, are important modulators of HS structure and function and ECM 
architecture (131).  
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Fig. 8. Illustration of CD/DS and HS/heparin synthesis showing the major enzymes involved in chain 
modifications.  GAGs are attached to the core protein by a tetrasaccharide linker on whom the sugar 
chain is assembled. Chondroitin syntase (ChSy) catalyze the chain elongation by addition of GalNAc- 
and GlcA, and generates CS or DS; GlcNAc- and GlcA-containing disaccharide units added by EXT-
activity generates HS/heparin. Successive modification by epimerization of GlcA to IdoA, 2-O-
sulphation, 4-O-sulphation and 6-O-sulfation in the case of CS or DS, and N-deacetylation–N-
sulphation, epimerization, 2-O-sulphation, 6-O-sulphation and 3-O-sulphation in the case of HS, 
results in mature GAG chains. NDST, N-deacetylase–N-sulphotransferase; OST, O-sulphotransferase. 
In the text, the terminology HSST (HS sulfotransferase) and CSST (CS sulfotransferase) is used rather 
than OST. This figure is taken from (132). 
 
Synthesis of CS/DS 
 
CS and DS chain synthesis is initiated by the addition of GalNAc to the linker by 
GalNAc transferase (GalNAcT) -1 (133). CS chains contain alternating GalNac and GlcA 
residues, while in DS the GlcA is epimerized into IdoA by DS-C5 epimerase (134), as 
illustrated in Fig. 8.  Several specific glycosyltransferases contributing to the chain elongation 
have been characterized. Chondroitin synthase 1-3 possess dual enzymatic activities, meaning 
  Introduction 
21 
both glucuronyltransferase and galactosaminyltransferase activity. Two other enzymes 
identified however, CSGlcA-T and CSGalNAc-T2, act by transferring GlcA or GalNAc, 
respectively (70). The sulfotransferases involved in the biosynthesis of CS/DS belong to three 
different families that transfer sulfate groups to C4 on GalNAc residues (C4ST), C6 on 
GalNAc residues (C6ST) or C2 on the hexuronic acid (70).  Three C4STs has been 
characterized (135,136), in addition to a DS-spesific GalNAc 4-O-sulfotransferase (D4ST-1) 
(137). The latter is suggested to work immediately after epimerization preventing back-
epimerization of the newly formed IdoA into GlcA. The sulfotransferases involved in the 6O-
sulfation of GalNAc residues are C-6 sulfotransferase 1-2 (C6ST1-2) and GalNAc 4-sulfate -
6-O-sulfotransferase (GalNAc4S-6ST) which sulfates C-6 on already 4-O sulfated GalNAc. 
The hexuronic acid can be sulfated in C-2 position by uronyl 2-O-sulfotransferase. CS/DS 
chains show a wide structural heterogeneity as a result of the variation in the repeating 
disaccharide units. The structure of CS depends on the animal species, tissue and 
physiological conditions (134). In contrast to HS however, few reports on post transcriptional 
modifications of CS are described.   
 
Synthesis of HA 
 
In contrast to HS/heparin and CS/DS, HA is not attached to a core protein and is 
assembled at the cell surface. It is not sulfated or subjected to other modifications. HA is 
produced by three HA synthase isoenzymes (HAS1-3), which are integral plasma membrane 
proteins whose active sites are located at the intracellular face of the membrane (138). These 
enzymes polymerize HA by repeatedly adding GlcA and GlcNAc the nascent polysaccharide 
as it is extruded via ABC-transporter through the cell membrane into the extracellular space. 
However, recent studies indicate that HA is not restricted to the extracellular milieu, but is 
also present intracellularly, implicated in inflammatory processes (139). 
 
Synthesis of KS 
 
KS is found predominately in cornea and cartilage. In KS, synthesis is initiated as N- 
or O-linked oligosaccharides, and is termed KS I-III depending on their oligosaccharide link 
to the core protein. KS is extended by alternating addition of Gal and GlcNAc and can be C-6 
sulfated at GlcNAc or both Gal and GlcNAc (140) . 
1.3.3 Functions 
PGs exert their functions trough interactions with other molecules through their 
protein core or GAG chains. In both HS/heparin and CS/DS, interactions with the GAG chain 
can be based either on electrostatic interactions or on sequence specific interactions. The latter 
depend on the precise location of N- and O-sulfate modifications along the sugar chain.  This 
sulfation pattern is important for the interactions with a range of GAG-binding proteins, such 
as several ECM components, growth factors, chemokines, cytokines (141), cell adhesion 
molecules, coagulation proteins and LPL (142). 
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Heparin is the most well-known GAG, used in the clinic for more than 75 years as an 
anti-coagulant. Heparin is an extensively sulfated form of HS, and has the highest negative 
charge density of any known biological molecule. Similar to HS in general, heparin can 
interact with other molecules through relative non-specific electrostatic interactions, or 
alternatively, by sequence-specific interactions. The sequence of heparin interacting with 
antithrombin is the best characterized of the protein-binding HS domains. Antithrombin 
inhibits thrombin and several other serine proteases of the coagulation pathway, including 
factors IXa, Xa, XIa and XIIa, and antithrombin, thus inhibiting coagulation. The ability of 
antithrombin to inhibit thrombin is greatly accelerated in the presence of heparin. The binding 
is mediated by a specific pentasaccharide sequence, which is hallmarked by the essential 3-O-
sulfated GlcNS unit (143):  
GlcNAc6S/GlcNS6S – GlcA – GlcNS3S6S – IdoA2S – GlcNS6S  
This sequence induces conformational changes in antithrombin which increase its inhibiting 
activities. However, the full thrombin-inhibiting activity of heparin requires an 
oligosaccharide of 18 monosaccharide units (144). Notably, the anticoagulant effect of 
exogenous heparin does not seem to correspond with the biological functions of endogenous 
heparin. Attached to the serglycin core protein, heparin is exclusively expressed in mast cells, 
important for storage of components associated with allergic and inflammatory responses. 
Thus, heparin seems important in situations not necessarily associated with blood coagulation. 
Recently however it was showed that heparin initiates the production of bradykinin via factor 
XII of the blood coagulation system and thus having an important role in allergy and 
inflammatory reactions driven by mast cells via the coagulation system (145). 
HSPGs other than heparin are expressed throughout the body, interacting with a range 
of different molecules and resulting in a multitude of biological activities. As with heparin, 
ligand-interaction specificity is determined by the positioning of sulfate groups on HS 
creating distinct binding motifs. HS – protein interactions vary with regard to specificity and 
may depend on charge density in addition to strict sequence motifs of HS. However, the 
extent of such specific interactions is questioned (146).  
Growth factors are among those important molecules in which function depend on 
GAG-interactions (147). Several angiogenic growth factors, such as VEGF (148), FGF-2, and 
PDGF, depend on HS/heparin for their biological effects.  
FGFs and FGF receptors (FGFR) play critical roles in the control of many 
fundamental processes such as cell proliferation, differentiation and migration, and there are 
23 known FGFs and 5 types of FGFRs in humans (149). Although the importance of HS in 
FGF signalling is well documented, the exact roles of HS in the signalling complex are less 
well characterized. A complex with 2:2:2 ratio between FGF1:HS:FGFR1 is proposed, where 
HS is essential for formation of the signalling complexes (149). FGF1 and FGFR1 are 
postulated to bind to the HS chain. During the activation, one FGF1 binds to one FGFR1 on 
the same HS chain and form a half-complex at the non-reducing ends. Two of these half-
complexes then associate and form the active molecular signalling complex. This is illustrated 
in Fig. 9 taken from (149). Among the sulfate groups on HS, sulfation at the 6-O-position of 
GlcN residues is required for FGF-FGFR interactions and signalling (150-154), but not for 
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ternary complex formation (149). QSulf1 is a HS 6-O-endosulfatase, and QSulf1 mediated 6-
O-desulfation reduce the formation of the FGF-HS-FGFR complex (151). 
 
 
Fig.9. A proposed mechanism 
for the formation of the 
FGF1-FGFR1 signaling 
complex. FGF1 and FGFR1 
bind to their binding sites on  
the HS chain. During the 
activation, FGF1 bind to 
FGFR on the same chain, 
forming a half-complex. Two 
of these half-complexes then 
associate to an active 
molecular signaling complex, 
taken from (149).
 
Changes in 6-O-sulfation can be on the level of biosynthesis, trough regulation of 
HS6ST. In the adult mouse HS6ST-3 are rather ubiquitously expressed, while HS6ST-1 and 
HS6ST -2 are seen in specific organs. HS6ST-1 knockout mice exhibit deficient HS 
biosynthesis, abnormal placental and organ morphogenesis and late embryonic lethality 
(153,154).  HS6ST-2, but not HS6ST-1, is mainly involved in the 6-O-sulfation of trisulfated 
units. HS6ST-2 KO mice survive and are fertile without apparent abnormal phenotypes, while 
HS6ST-1-/-/ HS6ST-2-/- mice die at slightly earlier age than HS6ST-1-/- mice. Alternatively, 
HS may be post-translationally modified through the action of two 6-O-endosulfatases, Sulf1 
and 2 (151). Deficiency in human Sulf 1 and 2 affected VEGF-mediated signaling and kidney 
function (155). 
Further emphasising the role of HS structure is the importance of 6-O-sulfation in HS 
interaction with L- and P-selectins. Selectins are a family of cell adhesion molecules 
important in inflammation. The anti-inflammatory effects of heparin in vivo is dependent 
primarily on P- and L-selectins, and the 6-O-sulfate group of GlcN units in heparin is critical 
for interaction with these selectins (156).  
LPL, which is an important enzyme in lipid metabolism, binds to HSPGs. This 
interaction is crucial for several aspects of LPL function. Although LPL has high affinity to 
highly sulfated HS and heparin oligosaccharides, it is suggested that LPL binds to the more 
commonly expressed modestly sulfated sequences and can make use of general features of the 
HS chains with N-sulfated domains interrupted by low sulfated N-acetylated disaccharides 
(60,157).  
Similarly to these HS sequences, various biological functions of CS/DS are thought to 
be attributed to particular domain structures with specific sulfation patterns (134,158). SLRPs 
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like decorin and bilglycan are able to interact with their ligands both through their GAG 
chains or the leucine rich repeats (LLRs) characteristically of their protein core. They have the 
ability to bind a multitude of molecules including collagens, Toll-like receptor (TLR), EGF-R 
(epidermal growth factor receptor), IGF-IR (insulin-like growth factor receptor) and TGFβ 
(159). However, the role of CS and DS fine structure in ligand binding has not been subjected 
to extensive research. 
1.3.4 PGs in diabetic nephropathy 
Diabetes is a disease eventually resulting in both micro- and macro-vascular damages, 
caused by the complex effects of the diabetic milieu on a range of components. Alterations in 
both PG expression and structure are important pieces in this puzzle, affecting several organs. 
The kidney is one of the most severely affected organs, resulting in 10-20 % of people with 
diabetes dying of kidney failure (WHO).  
Diabetes is the most common cause of chronic kidney disease, attacking 40 % of 
diabetics (160), and diabetic nephropathy is the cause of 44 % of all end-stage renal disease in 
the United States in 2009 (www.usrds.org). In Norway diabetic nephropathy is the cause of 
end-stage renal disease (ESRD) in 16-18 % of the patients entering renal replacement therapy, 
but another 15 % have diabetes as a covariant disease. Thus diabetes is part of the ESRD 
treatment in one third of the cases in Norway (Norwegian Renal Registry, www.nephro.no). 
The prevalence of T2DM is increasing both in Norway and worldwide. The relative 
prevalence of diabetic nephropathy is decreasing (161). Still, the diabetes epidemic leads to 
an increase in the absolute incidence of diabetic nephropathy. Understanding of the 
mechanisms behind the development of this disease is essential for the prevention of this 
prominent cause of end stage renal disease.  
One of the main functions of the kidneys is filtration of the blood, as well as playing a 
crucial role in maintaining homeostasis, e.g. by regulation of elecrolytes and maintenance of 
the acid-bace balance. The filtrating entity of the nephron, the glomerulus, acts as the filtering 
unit and keeps normal proteins and cells in the bloodstream, allowing extra fluid and wastes 
to pass through. The architecture of the kidney is illustrated in Fig. 10. 
Diabetic nephropathy is a progressive kidney disease caused by angiopathy of 
capillaries in the kidney glomeruli as a result of longstanding DM combined with poor blood-
glucose control and genetic predispositions. An early detectable change in the course of 
diabetic nephropathy is the thickening of the glomerulus. At this stage microalbuminuria is 
experienced; namely excessive leakage of serum albumin in the urine. As diabetic 
nephropathy progresses, the glomerular filtration rate (GFR) is further reduced and urine 
albumin increases to the point that it may be detected by ordinary urinalysis techniques. At 
this stage, a kidney biopsy generally clearly shows diabetic nephropathy, which is an 
indication for dialysis and kidney transplantation in the western world. 
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Fig. 10.  Illustration of the structure of the kidney and the nephrons, containing the filtrating unit, the 
glomeruli, taken from [http://www.unckidneycenter.org/kidneyhealthlibrary/glomerulardisease.html].  
 
The glomerular filtration barrier is considered to be composed of three layers as 
illustrated in Fig. 11: the innermost fenestrated glomerular endothelium with the glycocalyx 
facing the luminal side, a glomerular basement membrane, and the outermost layer of 
podocytes with the slit diaphragm. The role of the podocytes and the glomerular basement 
membrane in resisting free passage of macromolecules is undisputable. However, resent 
findings also emphasize the importance of the endothelium in this sieving (30,162,163). The 
components of the glomerular basement membrane are secreted both from the ECs and the 
podocytes. PGs are important constituents of this membrane, and with their negatively 
charged GAG chains they are hypothesized to contribute to the selective sieving, preventing 
negatively charged serum proteins such as albumin from passing from the bloodstream to the 
urinary space.  
In diabetes, the structure of the glomerular basement membrane is altered and 
becomes thicker, but also more disorganized and permeable (164) . An increase in ECM 
components but a reduction in the major basement membrane PGs perlecan, collagen XVIII 
and agrin is observed. In the mesangium and the interstitial space however, diabetic 
nephropathy is associated with an increase in CS/DS PGs decorin and biglycan (82). In 
addition to the glomerular basement membrane, the glycocalyx of glomerular endothelial cells 
also contribute to the selective sieving of the glomerular capillary wall (36). The glycocalyx is 
a negatively charged dynamic network of PGs and glycoproteins, covering both the fenestral 
and interfenestral regions of the luminal side of the ECs. This structure too is affected by the 
alterations in PG expression and charge which are observed in diabetic nephropathy (165) and 
a reduction of this barrier is seen in vascular dysfunctions also describing in diabetes (34). 
Thus, decrease in PG expression or sulfation is factors proposed to contribute to a reduced 
filtration capacity.   
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Fig. 11. Schematic drawing of the glomerular 
barrier and its 4 major layers, namely the 
podocyte slit membrane (Podo), the 
glomerular basement membrane, the 
fenestrated capillary endothelium (Endo), and 
the endothelial cell surface layer, often called 
the glycocalyx (Glyco). Taken from (163).  
 
In hyperglycemia there is an increased flux trough metabolic pathways such as the polyol 
pathway, the hexosamine pathway, the PKC pathway and the AGE-pathway (53). Diabetic 
nephropathy develops partly because of these changes in glucose metabolism, but also as a 
consequence of genetic predisposition (166).  
HS is the dominating GAG expressed in the kidney (167), and has received more 
attention than CS/DS when exploring the roles of PGs in glomerular filtration (90). The 
functions of HSPGs in renal filtration have been addressed by a series of studies. Several 
early studies on human biopsies implicated a reduction of HSPG expression in the impaired 
glomerular filtration (168-171). This was further supported by several observations in animal 
models (172-175).  Common animal models are rats made type 1 diabetic with streptocotozin, 
as well as the genetically modified obese db/db mice, lacking leptin receptor signaling, and 
representing a good model for human T2DM. As well as a reduction in HSPG expression, a 
decreased sulfation was also reported to contribute to proteinuria (176). Heparanases and 
sulfatases are enzymes capable of posttranslational modification of HS, possibly contributing 
to reduced HS or reduced sulfation, respectively. Several publications suggest that heparanase 
may play a role in modifying HS structures in glomeruli, and that this is relevant in diabetes 
or diabetic nephropathy (130,177-179). Additionally, altered activity of 6-O-sulfatase is also 
implicated in PG structure in kidney (155). The matrix metalloproteinases (MMPs) are also 
important in matrix and PG turnover, and MMP levels are increased in plasma and urine from 
diabetic patients (180). 
However, some of the more recent studies contradict the observations (181-183), and 
this has made the role of HSPGs in glomerular filtration a highly debated issue (181,184,185). 
HS is the dominating GAG in the adult kidney receiving the majority of attention, 
while CS/DS is only 10-20 % and is less studied. Of the few reports available on CS in renal 
filtration, one demonstrated an increase in CS/DS content in streptozotosin treated rats (186), 
while in another study a reduction in DS, HS and HA was accompanied by unaltered levels of 
CS (187). A recent study however, also on streptozotosin-induced diabetic rats, showed a 
reduction not only in HS expression, but also in CS/DS expression and sulfation in the 
diabetic kidney (188). Several studies implicate decorin and biglycan as the most important 
SLRPs in kidney, present mainly in the interstitium (189). Increased renal biglycan in diabetic 
mice was suggested to contribute to renal lipid accumulation and the subsequent development 
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of diabetic nephropathy (190). Their roles probably extend beyond those as structural matrix 
components, and include a role of soluble signaling molecules involved in kidney disease 
(82). However, their presence in the basement membrane has not been a focus of intensive 
study as the number of studies on the biology of CSPGs present in basement membranes has 
been low compared to their HSPG counterparts. The few studies on this topic include the 
description of CSPGs bamacan in basement membrane (191) and leprecan in glomerular 
basement membrane (192). As alterations in glomerular filtration are accompanied by 
changes in CSPGs, their role in the glomerular basement membrane deserves increased 
attention, particularly in light of the debated importance of HSPGs in the filtration barrier 
(181,184). 
HA is also an important interstitial matrix component found in the renal papilla, but is 
scarcely expressed in the cortex. Due to its negative charge, HA has large water-binding 
capacity, and has important functions in renal water handling. Alterations in HA is observed 
in the diabetic kidney. Papillary HA was increased in diabetic rats (193) and increased 
glomerular HA synthesis has also been shown in glomerular core cultures from control and 
stre ptozotocin-diabetic rats (194), regulated trough HAS2 (195).
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2 Aims of study 
 
PGs are important matrix molecules with multiple functions, shown to be involved in several 
aspects of diabetic complications. Endothelial dysfunction, resulting from hyperglycemia and 
inflammation, is important in these processes. The overall aim was to obtain a better 
understanding of the expression and functions of the PGs in relation to endothelial 
dysfunction. 
Specific aims were to: 
 Study the effect of hyperglycemia and inflammation on PG structures in primary 
human endothelial cells. 
 Gain further insight into the biosynthesis and secretion of PGs from polarized 
endothelial cells.  
 Study the importance of PGs in relation to the endothelial proliferative status.  
 To study the effects of diabetic conditions on GAG structure in one of the organs 
affected by diabetes, the kidney.
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3 Summary of results 
 
Paper I:  
 
Reine TM, Kusche-Gullberg M, Feta A, Jenssen T, Kolset SO. 
Heparan sulfate expression is affected by inflammatory stimuli in primary human 
endothelial cells.  
Glycoconj J. 2012;29:67-76. 
 
In this study we investigated the effects of hyperglycemic and inflammatory 
conditions on endothelial PGs, relevant for the diabetic setting. De novo secretion of 35S-PGs 
was studied in HUVEC exposed to hyperglycemia or the inflammatory mediators TNFα, IL-
1α, IL-1β or TGFβ. The effect on total 35S-PG secretion and size distribution as well as HS 
and CS chain length, followed by HS polyanionicity and HS disaccharide composition, was 
examined.  
We found no effect of hyperglycemia on neither of these parameters. In inflammatory 
conditions, no changes were observed in the overall 35S-PG size or in the 35S-CS chain length, 
indicating that CSPG expression was unaffected.  The HSPGs however, were affected to 
various degrees. HS chain length was increased with TNFα and decreased with TGFβ, while 
both lead to a decrease in the overall 6-O-sulfation. IL-1α on the other hand, was related to an 
increase in 6-O-sulfation, but had no effect on chain length. IL-1β had no effect on these 
parameters. However, IL-1β was the only factor with stimulatory effects on 35S-PG secretion.  
These results indicate that endothelial PG expression is unaffected by hyperglycemia, 
while different inflammatory stimuli had distinct, but different effects on endothelial HSPG 
expression.   
 
 
 
Paper II:  
 
Meen AJ, Øynebråten I, Reine TM, Duelli A, Svennevig K, Pejler G, Jenssen T, Kolset SO.   
Serglycin is a major proteoglycan in polarized human endothelial cells and is implicated 
in the secretion of the chemokine GROalpha/CXCL1. 
J Biol Chem. 2011;286:2636-47 
In this paper we studied the secretion of PGs from endothelial cells further. Culturing 
HUVEC on semipermeable filters allowed for the identification of serglycin as a major PG 
expressed by HUVEC, secreted predominantly to the apical side of these cells. Further, we 
studied the intracellular localization of serglycin in endothelial cells, as this has not been 
extensively studied. Serglycin could be detected in perinuclear regions corresponding to the 
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Golgi, as well as in two different types of secretory vesicles throughout the cytoplasm, 
identified by immunostaining and confocal microscopy. IL-1β stimulation increased the 
amount of serglycin-containing vesicles, in particular the smallest of the vesicles, 
corresponding to the type 2 granules. Also, following IL-1β stimulation, co-distribution with 
GROα/CXCL-1 was observed in a portion of the type 2 granula, suggesting interactions 
between these molecules. Further; abrogation of CS-chains with xyloside reduced the 
vesicular CXCL-1 expression, as well as the CXCL-1 secretion.  
Together, these results indicate that serglycin is a major PG in endothelial cells, 
mainly secreted to the apical side and with possible roles in storage and secretion of 
inflammatory cytokines.   
 
 
Paper III:  
 
Reine TM, Vuong TT, Meen AJ, Jenssen T, Kolset SO  
Serglycin expression is reduced in quiescent primary endothelial cells  
Submitted manuscript 
As serglycin was found to be highly expressed in HUVEC, we aimed to investigate the 
functional implications of serglycin expression in endothelial cells further, focusing on 
proliferation. Sparse proliferating cell cultures are relevant for studies on angiogenesis and 
wound healing, while dense cultures are relevant for the quiescent endothelium lining the 
blood vessels.  
De novo total 35S-PG secretion was reduced with 70 % in dense compared to sparse 
cell cultures. When investigating the secretion of individual PGs however, this was not a 
unifying pattern for all PGs. Reduced expression in dense cultures was evident for the highly 
expressed serglycin and biglycan, as well as decorin, but not for versican or collagen XVIII. 
Endocan and syndecan-4 levels on the other hand, were unaffected by cell density. 
IL-1β stimulation revealed a more pronounced increase in 35S-PG secretion in dense 
cell cultures, which was also reflected in both protein and mRNA levels of the dominating 
PGs serglycin and perlecan. Versican, syndecan-4 and endocan on the other hand, increased 
irrespective of cell density, while decorin and biglycan secretion was not affected after this 
stimulus.  
In sparse cultures, serglycin was localized to perinuclear regions corresponding to the 
Golgi, as well as in intracellular vesicles. In contrast, in dense cultures there was an obvious 
decrease in the Golgi staining, but extensive staining in intracellular vesicles. IL-1β 
stimulation increased the serglycin positive vesicles in both sparse and dense cultures, 
combined with a modest reduction in Golgi staining of the sparse cells. 
These results indicate a relationship between serglycin expression and localization, 
with the proliferative status of the cells, as well as an effect of inflammatory stimuli on 
serglycin synthesis and secretion. 
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Paper IV:  
 
Reine TM, Grøndahl F, Jenssen T, Hadler-Olsen E, Prydz K, Kolset SO  
Reduced sulfation of chondroitin sulfate but not heparan sulfate in kidneys of diabetic 
db/db mice 
Manuscript 
Changes in kidney function in relation to diabetes involve a series of factors, including 
PGs. The PGs are hypothesized to contribute to the filtration barrier trough the action of their 
highly polyanionic GAG chains, and we wanted to further investigate the roles of PGs in this 
context.  
The kidney of diabetic db/db mice was compared to that of their non-diabetic db/+ 
controls. There was no observed difference in the distribution of important basement 
membrane components collagen IV and perlecan, as analyzed by immunohistochemistry. 
Furthermore, the cortex, rich in the filtrating glomeruli units, was isolated. GAGs were 
extracted from this material, and subjected to enzymatic treatment followed by analysis of the 
disaccharide composition. The GAG recovery was 74-75% HS, 18-20% CS/DS and 6 % HA, 
which was not significantly different between the two groups. The sulfation pattern of HS and 
CS/DS was compared, and no difference in HS composition was observed. However the 
sulfation of CS was significantly reduced in diabetic kidney cortex. In the healthy db/+ mice 
the 4-O- and 6-O-sulfated CS were 65.1 % and 10.8 % respectively, of the total sulfated CS. 
In the diabetic db/db mice these numbers were reduced to 40.2 % and 6.2 %. This is a 
reduction of 41 % of the total 4-O- and 6-O-sulfated in the db/db mice compared to db/+, with 
a corresponding increase in unsulfated sugars. 
The role of PGs in kidney filtration and kidney disease is a highly debated issue, with 
focus on the role of the HSPGs. These findings showing no effect on HS structures, but rather 
a decrease in sulfation of CS in diabetic kidneys, should be taken into consideration when the 
importance of PG changes in this organ is addressed. 
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4 General discussion 
 
Diabetes is characterized by chronic hyperglycemic and inflammatory conditions. 
Endothelial cells are continuously exposed to and affected by these environmental factors, 
resulting in endothelial dysfunction. PGs are produced by endothelial cells as well as other 
tissue-specific cells, and are important structural and functional components of the 
vasculature. Endothelial dysfunction is related to several diabetic complications, including 
diabetic nephropathy. The roles of the PGs in these settings are intriguing, while still a rather 
unexplored field.  
 
Endothelial PGs are important constituents of the glycocalyx, important for rolling and 
homing of lymphocytes (34,59), as well as prominent components of the endothelial basement 
membranes and ECM (69). Thus, changes in PG biosynthesis and turnover may affect several 
aspects of endothelial functions. PGs interact with partner molecules trough their protein core, 
or more importantly, through their GAG chains. Some of these interactions rely solely on 
electrostatic interactions, while others are dependent on precise structural patterns of the GAG 
chain (142,144,146). Several studies emphasize the importance of changes in HS expression 
and structure in endothelial dysfunction (58,196,197). 
In order to shed more light on the roles of PGs in diabetes, we used primary human 
endothelial cells as an experimental system to study the effects of diabetic conditions on PG 
structure and functions. HUVEC is a relevant cell system for studies on major human diseases 
such as diabetes and atherosclerosis (198). In contrast to permanent cell lines, these primary 
cell cultures mirror the genetic diversity of their donors, more relevant for the in vivo 
situation. In HUVEC, differences between donors are sees in cytokine, CAM, NO and 
endothelin secretion, while production of vWF and MMP-1 is reported to be stable (68).  
The endothelial cells throughout the body are heterogeneous, with variations in 
features and functions in different organs. Both  continuous,  fenestrated and discontinuous 
endothelium exists (41), and there are phenotypic variations between ECs located at different 
portions of the vascular tree, and between arterial and venous cells  (199). Accordingly, 
endothelial cells from different vascular beds show differences in e.g. the PG profile (200) 
and respond differently to identical stimulus (201). Thus, generalizations on endothelial cell 
functions from our findings in HUVEC should be done with caution, as these cells represent a 
unique and specialized part of the vasculature. 
Normal endothelial cells can be regarded as quiescent as their turnover is 
approximately 1 year (41), being contact growth-inhibited and protected from apoptosis (39). 
By contrast, in proliferating endothelial cells, such as during angiogenesis or wound healing, 
their behavior is comparable to that of in vitro sparse cell cultures, which are sensitive to 
growth-factor stimulation (39). Thus, in cell culture experiments, different outcomes would be 
expected in cells cultured at different densities. Additionally, our studies were restricted to 
cells passaged no more than 4 times, as the cell culture properties could change with passage 
number (202) as seen for the expression of vWF (203). 
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In paper I, we studied the impact of hyperglycemia as well as several inflammatory 
stimuli on the de novo secreted endothelial 35S-PGs. The effect on total 35S-PG secretion and 
size distribution as well as HS and CS chain length, followed by HS polyanionicity and HS 
fine structure, was examined. We could not detect any effect of hyperglycemia on neither of 
these parameters. Due to the profound effect of high glucose levels on endothelial dysfunction 
(204), this was a rather unexpected observation. A previous study on HUVEC showed a 
reduced PG secretion in hyperglycemia, but the experimental conditions were not the same as 
in this study (205). On the other hand, an increased GAG secretion was observed in PAEC 
(porcine aortic endothelial cells) (206) when the cells were cultured under hyperglycemic 
conditions. However, with the parameters used in this study HUVEC seem to be relatively 
robust when it comes to short term hyperglycemic conditions. 
In contrast to hyperglycemia, we observed effects with inflammatory stimuli. CSPGs 
were not affected, while HSPGs were affected differently by the different inflammatory 
agents. HS chain length was increased with TNFα and decreased with TGFβ, while both 
induced a decrease in 6-O-sulfation. IL-1α on the other hand, was the only cytokine to give an 
increase in 6-O-sulfation, but had no effect on HS chain length. HS is shown to modulate 
inflammatory reactions by interactions with inflammatory cytokines (58), and 6-O-sulfation is 
important also in such interactions, exemplified by IL-8 interactions with HS (207). 
Interestingly, the different inflammatory cytokines in our study had different effects on PG 
expression and structure. IL-1β had no effect on chain length or sulfation pattern, but was the 
only factor with significant stimulatory effects on 35S-PG secretion. TNFα, TGFβ and IL-1α 
on the other hand affected HS chain length and/or sulfation pattern, notably in different 
directions.  
HS fine structure is shown to be vital for interactions with partner molecules 
(208,209).  The NDST-enzymes catalyzing the N-deacetylase / N-sulfotransferase 
modifications of HS come in four isoforms, where NDST-1 and -2 are found in most cells 
(210). The activities of NDSTs are a prerequisite for further modifications of HS, the 
importance of which is illustrated by the lethality of the NDST-1 knockout mice (209) and the 
effects on storage granules in mast cells of NDST-2 knockout mice (110,211). Hepatic NDST 
was suppressed 2 weeks after induction of T1DM in rats (212), and NDST mRNA was 
negatively correlated with blood glucose (213), illustrating a role for NDST and chain 
modifications in HS. However, in adipocytes, NDST expression and activity was not affected 
by hyperglycemia (214) and, in cultured fibroblast from diabetic patients with or without 
nephropathy, no difference in NDST expression was observed (215).  
6-O-sulfation has proved to be particularly important for several HS interactions, 
including FGF-FGFR and VEGF:VEGF-receptor (VEGFR) interactions and signaling 
(149,197,216).  6-O-sulfation is catalyzed by HS6ST1 - 3 (70,217), having similar substrate 
specificity but differences in tissue expression. Altered expression of these enzymes will also 
affect the sulfation pattern of HS and affect HS functions. Furthermore, HS6ST1 -/- mice 
show defective HS synthesis, reduced embryonic survival, growth retardation and tissue 
abnormalities, illustrating the importance of this specific modification (153,154).  
The modification of HS structure does not stop at the biosynthetic level however; the 
level of 6-O-sulfation is also regulated by the post-transcriptional action of the Sulfs (218). 
  General discussion 
34 
Accordingly, qSulf1 inhibited FGF signaling in mesoderm induction and angiogenesis (151). 
Some studies suggest a role for sulfatases in structural HSPG changes of diabetic kidney, such 
as the development of proteinuria in Sulf deficient mice  (155). It has also been shown that the 
anti-inflammatory effect of heparin is due to binding to L- and P- selectin, blocking their 
interactions with cell surface HS. These interactions are dependent on 6-O-sulfate groups 
(156). The existence of a specific 6-O-sulfatase, without the apparent existence of other HS 
sulfatases, add another level of regulation and  might suggest the 6-O-sulfation to be a 
particular important structural feature of the HS chain. 
From the data presented in this study it is evident that even a short term exposure to 
inflammatory conditions is likely to affect HS structure. The biological relevance of these 
results could profit from further studies on interactions between chemokines or growth factors 
and HS with different degrees of 6-O-sulfation.   
 
In paper II HUVEC were cultured on semipermeable filters to study polarized 
secretion of PGs. This cell culture system is a useful supplement to conventional culturing 
techniques and gives the opportunity to obtain more extended data on endothelial cell biology.  
In this study we identified serglycin as a major PG expressed by these cells, secreted 
predominantly to the apical side. This apical secretion of serglycin is intriguing. PGs are 
important components of the basement membrane, and a basolateral secretion could be 
expected, as we observed for decorin and perlecan. Apical secretion on the other hand 
suggests roles for serglycin as part of the endothelial glycocalyx or in the circulation. The 
presence and importance of the endothelial glycocalyx is a field receiving increasing attention 
(33-36), although some questions the presence of this structure in in vitro endothelial cultures 
(219). Serglycin from HUVEC is substituted with CS-chains, and these data are in line with 
observations in polarized MDCK-cells, which suggest that CS is a signal for apical sorting 
(220,221). 
The intracellular localization of serglycin in endothelial cells has not been extensively 
studied. Our observations of immunostained serglycin by confocal microscopy demonstrated 
the presence of serglycin in perinuclear regions corresponding to the Golgi compartment, as 
well as in two different secretory vesicles found throughout the cytoplasm. In paper I we 
found that PG expression was unaffected by hyperglycemia, but stimulated by exposure to IL-
1β.  This cytokine is an important mediator of inflammatory responses, and elevated levels are 
predictive of T2DM (64). Endothelial cells are both able to secrete and to respond to stimuli 
mediated by this cytokine, as they express IL-1R1 (31).  This motivated for further 
investigations of the effects of IL-1β on PG expression in HUVEC. Thus, as we identified 
serglycin as a dominating PG, we investigated further the effects of IL-1β on this particular 
PG. Data obtained showed that IL-1β stimulation increased the amount of serglycin-
containing vesicles in particular in the smallest of the vesicles, corresponding to the type 2 
granules. These granules contain the chemokine CXCL-1 (GROα) as well as CCL-2 (MCP-1) 
(50), and when HUVEC is exposed to IL-1β, the secretion of CXCL-1 is stimulated (49). As 
serglycin is important for the storage and secretion of numerous components in hematopoietic 
cells (102,109), we wanted to investigate if serglycin had a similar role in endothelial cells. 
Following IL-1β stimulation, co-distribution with CXCL-1 was observed in a portion of the 
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type 2 granula, suggesting interactions between these molecules. Further support for this 
notion was obtained by abrogating of CS attachment to core proteins with xyloside, which 
reduced the vesicular CXCL-1 expression as well as the CXCL-1 secretion.  
These results are compatible with a role for serglycin in regulation of inflammatory 
responses of endothelial cells. Serglycin is important for the granule storage of  proteases and 
histamine in mast cells (109), granzyme B storage in cytolytic T-cells (112), for chemokine 
and platelet derived growth factor storage in platelets (111) and TNFα-secretion in 
macrophages (108). Serglycin interacts with several potent and important biological 
molecules both in storage granules and secretory vesicles in several cell types. Accordingly, 
our results support a similar role for serglycin in endothelial cells, promoting storage and 
secretion of inflammatory cytokines in response to inflammatory stimuli.   
 
Serglycin was found to be highly expressed in HUVEC. In paper III we aimed to 
investigate the functional implications of serglycin expression in endothelial cells further, 
focusing on serglycin expression and proliferation. Dense monolayers of cultured endothelial 
cells resemble the quiescent endothelium coating the vasculature (45). These cells are contact-
inhibited and non-proliferative. Sparse cell cultures in contrast, are proliferating and respond 
differently to stimuli, and this experimental system can be related to endothelial cells in 
wound healing or angiogenesis (39,42). Diabetes is recognized by a chronic low-grade 
inflammatory state, affecting the entire vasculature and promoting endothelial dysfunction 
(51,222,223). In vitro experiments in dense endothelial cell cultures are relevant for this 
situation. Furthermore, impaired wound healing is an important aspect of diabetes (224), and 
angiogenesis is an important issue in diabetic retinopathy (225,226). These aspects can be 
studied experimentally using sparse endothelial cell cultures, which was done in this study 
with focus on serglycin expression and intracellular localization.  
De novo 35S-PG secretion was reduced 70 % in dense cultures. This was due to a 
decreased expression of serglycin and biglycan, whereas the expression of perlecan and 
versican increased in dense cultures. Accordingly, protein-levels and gene-expression of the 
dominating CS/DSPG serglycin was reduced in dense as compared to sparse cultures. IL-1β 
stimulation revealed that the response in 35S-PG secretion was more pronounced in dense cell 
cultures. This was observed for serglycin, as well as the highly expressed perlecan, but not the 
prominent SLRP biglycan. The increase in 35S-PG secretion could potentially be caused by 
increased sulfation or molecular size of the 35S-GAG chains.  This is however contradicted by 
our findings in paper I, showing no effect of IL-1β on these parameters. It must be noted, 
however, that the experiments in paper I were performed in subconfluent cultures.  
The striking difference in serglycin secretion in sparse and dense cell cultures was 
further investigated by immunocytochemistry. In accordance with the observations from 
paper II, sparse and subconfluent cultures contained serglycin in perinuclear regions 
corresponding to the Golgi apparatus, as well as in intracellular vesicles. In contrast, there 
was an obvious decrease in the Golgi staining in dense cultures, but extensive staining in 
intracellular vesicles. This might be interpreted as a decrease in serglycin synthesis and 
secretion, with an increase in vesicular serglycin for storage of secretory products. The data 
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obtained clearly shows that serglycin expression and localization is related to the proliferative 
status of the cells. 
Finally, after IL-1β stimulation, we observed an increase in serglycin positive vesicles 
in both sparse and dense cultures, with a modest reduction in Golgi staining of the sparse 
cells. These results are compatible with an increased serglycin synthesis and secretion 
following IL-1β stimulation. Although speculative, it can be suggested that in sparse HUVEC 
serglycin is involved in proliferation, while in quiescent cells it is more involved in 
inflammatory processes. Several PG binding chemokines are involved in both wound repair 
and angiogenesis (59,227,228), and some are known to interact with serglycin (102). 
Further work on this issue should include identification of serglycin partner molecules 
in endothelial cells. Performing co-immunoprecipitation with serglycin and growth factor or 
chemokine antibodies could be a valuable experimental approach. Another interesting 
experiment would be to knock down serglycin expression of subconfluent and quiescent cells 
using si-RNA, and investigating the effects on proliferation and inflammatory responses. 
However, the most useful tool in the search of serglycin functions is the serglycin knockout 
mouse, providing in vivo information. These mice are viable and fertile, but aged knock-out 
animals have splenomegaly, which suggest that growth of certain tissues is affected by 
serglycin (229). It has also recently been demonstrated that human endothelium activated by 
UV-irradiation showed increased expression of serglycin (230). Serglycin has also been 
shown to be involved in the regulation of apoptosis in mast cells (231). These findings 
support the involvement of serglycin in inflammation and regulation of apoptosis and 
proliferation. 
 
Diabetic nephropathy is one severe complication of diabetes. PGs are important 
structural components of the kidney, and have long been regarded as important filtration 
components of the glomerular basement membrane and in the endothelial glycocalyx. This is 
hypothesized to be due to the striking polyanionicity of these molecules, inhibiting the 
negatively charged serum proteins from passing from blood circulation to the urine (90). 
HSPGs are the dominating PG forms in the kidney, and have been regarded as the most 
important PGs in this organ. Both HSPG levels, and also degree of sulfation, are regarded as 
important factors in renal filtration, and have received more attention than CS/DS PGs. In 
early analyzes on human biopsies, a reduction in both HSPG expression and sulfation was 
reported in diabetes and kidney failure (168-171). This was supported by experiments on 
diabetic animal (172-175). However, in more recent publications, this relation has been 
questioned, which has made the role of HSPGs in glomerular filtration a highly debated issue 
(181-185).  
We wanted to investigate further the role of PGs in kidney filtration in diabetes. In 
paper IV we analyzed kidneys from diabetic db/db mice, and compared these to their non-
diabetic db/+ counterparts. The db/db mouse lack leptin receptor signaling, and is a much 
used animal model for T2DM (232). However, it is important to remember that lipid 
metabolism in mice and men are very different, manifested by the fact that mice do not 
develop atherosclerosis. Furthermore, streptozotosin-treated mice and rats are also common 
animal models when studying diabetes. One should keep in mind that such experimental 
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systems are models for T1DM rather than T2DM. Additionally, there could be differences 
between mice and rats related to several aspects of diabetes pathology.  
In addition to immunohistochemistry analysis of the kidneys, the cortex, rich in the 
filtrating glomeruli units, was isolated. GAGs were extracted from this material, and we found 
a composition of 74-75 % HS, 18-20 % CS/DS and 6 % HA. This is in accordance with a 
previous report on the GAG composition in adult kidney cortex (233). Also, this distribution 
was not different between the diabetic and the control animal. Further, the sulfation pattern of 
HS and CS/DS was compared between the two groups. In line with several of the more recent 
publications (181-183), no difference in HS composition was observed; further questioning 
the possible role of HS in diabetic nephropathy. Surprisingly, however, the sulfation of CS 
was significantly reduced in diabetic kidney cortex.  
The structure of CS/DS has been shown to be important for partner molecule 
interactions (134). Several organs of the C6ST -/- mouse were affected (234), and structural 
alterations of CS/DS have been implicated in pathological conditions such as atherosclerosis, 
where the amount of 6-O-sulfated CS was increased (134). In murine diabetic kidney a 
decrease in CS/DS content accompanied with a decrease in disaccharides with 4- and 6- 
sulfated CS (D0a10 or CS-E) was observed (233). Also, changes in CS/DS PGs such as 
decorin and biglycan (82,235), as well as NG2 (236) have been reported in kidney. The 
reduction in CS sulfation patterns in the diabetic kidney, however, is novel information. The 
possible importance of changes in CS structure in diabetic kidneys has not been studied to any 
great extent. Our data suggest that such changes should be taken into consideration when the 
importance of PG in diabetic nephropathy is addressed. In future studies it will be of great 
interest to investigate whether the changes observed in this study in mice can be seen also in 
the human diabetic kidney. 
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5 Conclusions 
 
Our studies have focused on the implications of HS and CS/DS PGs in diabetes, 
especially those derived from the endothelium. The field of PG biology in this regard has 
mainly focused on the HSPGs. We have confirmed that HUVEC indeed express several 
HSPGs which are altered by the diabetic conditions. However, we also identified the CS/DS 
PG serglycin to be a prominent PG expressed by endothelial cells. This is the major 
intracellular PG, and our work suggests a role for serglycin in the endothelial storage and 
secretion of different biologically active signaling molecules. This may have impact on 
regulation of endothelial cells in inflammatory reactions and regulation of angiogenesis.  
Unraveling the different functions of both HSPGs and CSPGs in normal and 
pathological settings is a fascinating and demanding task. More knowledge of these 
ubiquitously expressed molecules is of importance for a range of processes, and will provide 
valuable knowledge in relation to e.g. diabetes, which has been the main focus of this study.  
Further studies on serglycin should address its molecular partners under various 
conditions, using co-immunoprecipitation. Further information can be achieved by applying 
siRNA knockdown of serglycin, or furthermore, by more functional studies using the SRGN -
/- mice.  
The high expression and multiple possible roles of CS/DS PG serglycin emphasize the 
importance of CS/DS structural interactions in addition to the more studied HS. This notion is 
supported by our finding in diabetic kidney, showing an effect on CS structure only in the 
diabetic mice. Thus, more structural studied should be focused on the possible CS- changes in 
diabetes, preferably using human material such as kidney biopsies.  
 
 
 
* 
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Background: The implications of proteoglycans in kidney filtration are debated.
Results: The sulfation of chondroitin sulfate, but not heparan sulfate, was reduced in diabetic 
mouse kidney.
Conclusion: Chondroitin sulfate structure is relevant for studies on kidney function.
Significance: These results are relevant for understanding the functions of heparan sulfate 
and chondroitin sulfate proteoglycans in diabetic nephropathy.  
 
 
SUMMARY
Changes in kidney function in relation to diabetes involve a series of factors, including 
proteoglycans (PGs). These highly polyanionic molecules have been hypothesized to 
contribute to the filtration barrier in kidney glomerulus and possibly also in the glycocalyx of 
endothelial cells. To investigate potential PG changes in the diabetic kidney we isolated 
glycosaminoglycans (GAGs) from the kidney cortex of the diabetic db/db mouse strain and its 
corresponding control, the db/+ mouse. Tissue sections were analyzed using antibodies 
against one of the major basement membrane PGs, perlecan. No difference in staining for this 
PG was observed between kidney sections from the two mouse strains, nor was there any 
difference in the staining of collagen IV, the major collagen in basement membranes. On a 
molar basis there was no difference in the amount of GAGs, nor in the ratio of hyaluronan 
(HA) / heparan sulphate (HS) / chondroitin sulfate (CS). Disaccharide analyses of HS did not 
reveal any differences between material from db/db and db/+ mice when analyzed by HPLC. 
Likewise, no difference was observed for the amount of HA in kidneys from the two mouse 
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strains. In contrast there was a decrease in the sulfation of CS in kidneys from the db/db mice 
compared to corresponding material from db/+ mice. The proportion of 4-O-sulfated 
disaccharides (D0a4) was reduced from 65 % to 40 %, while 6-O-sulfated disaccharides 
(D0a6) were reduced from 11 % to 6 %. A corresponding increase in unsulfated disaccharides 
was observed. The data presented show a decrease in sulfation of CS in diabetic kidneys, 
which should be taken into consideration when the importance of PG changes in this organ is 
addressed. 
 
INTRODUCTION
 
Kidney filtration of blood and the formation of urine is a complex process. Both cell 
surface components on endothelial cells and podocytes, as well as extracellular matrix (ECM) 
components in basement membranes (BMs), play important roles in glomeruli, tubules and  
the tubulointerstitial space (1). Early animal experiments demonstrated that the glomerular 
BM is an important filtration barrier (2) and later it was shown that heparan sulfate (HS) 
proteoglycans (PGs) are part of this BM (3). Studies showed that native ferritin reached the 
urinary space in perfused kidney after removal of HSPGs with heparinase treatment (4), 
suggesting that HSPGs have functions related to kidney filtration.  The hypothesis 
investigated, based on these and similar findings, has been that HSPGs contribute to the dense 
distribution of negative charges in kidney BMs preventing serum proteins such as albumin 
from passing from the circulation into the urinary space. Several studies have addressed this 
hypothesis.  Injecting a monoclonal antibody against HS epitopes resulted in proteinuria in 
rats (5).  Further, collagen XVIII deficient mice had expanded glomerular basement 
membranes and increased serum creatinine, suggesting that kidney filtration was affected (6). 
Also, when the attachment region for HS chains in domain 1 was deleted in perlecan, mice 
with this deleted perlecan gene developed proteinuria (7).  In human studies, biopsies from 
patients with diabetic nephropathy showed decreased staining of agrin and HS epitopes (8). 
The importance of HSPGs for kidney filtration has however been questioned in several 
studies. Knock-out of agrin in podocytes did not result in proteinuria (9). Also, knocking out 
the HS polymerase system (exostosin-1, EXT1) in podocytes affected cellular morphology 
but was not accompanied by albuminuria (10).  
The complexity of this issue has been reviewed (11,12) and debated (13) and concerns 
several factors that contribute to kidney filtration, such as the nephrin slits and glycocalyx on 
endothelial cells.  Changes in HSPGs in the tubulointerstitial space also contribute to 
proteinuria (14). It is of interest to note that mutating an enzyme important for sialylation of 
podocalyxin, resulted in hyposialylation and proteinuria (15), highlighting the importance of 
other negatively charged components than PGs in kidney filtration.   
The major part of glycosaminoglycans (GAGs) in adult kidney is HS, but in the 
embryonic kidney the amount of chondroitin sulfate (CS) can be as high as 75 % (16), 
demonstrating the potential for GAG changes in the kidney, depending on external signals.  It 
has also been demonstrated that the BM contains CSPGs (17) which can be important for the 
filtering process (18). 
Some studies suggest that changes in the sulfation patterns of kidney HSPGs in 
diabetes can be due to increased local levels of heparanase (19), or changes in the regulation 
of sulfatases (20).  Increased levels of heparanase has been demonstrated in the blood of 
patients with diabetes, which might contribute to the development of kidney complications 
(21). 
Comparison of HS structures in kidney or other tissues from diabetic and control 
animals have been made in some studies. Early studies showed that the sulfation of HSPGs 
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from livers and cartilage explants from diabetic rats were less sulfated than control material 
(22,23). In contrast, no changes in HS structure were observed in a recent study using livers 
from diabetic mice (24). Also, glomerular HS structure in diabetic rats was not affected (25). 
However, another study focusing on HS in kidneys, showed that the larger glomeruli in 
kidneys from diabetic rats contained HS with a lower degree of N-sulfation compared to 
controls (26).   
Few studies have focused on CS/DS (dermatan sulfate) changes in the diabetic kidney. 
In diabetic rats a decrease in CS/DS content of kidneys was observed, accompanied by a 
decrease in the content of disaccharides of the D0a10 (CS-E) type (27).  
To investigate further the possible relationship between diabetes and structural 
changes in HS and CS/DS in the kidney we isolated these GAGs from cortex of kidneys taken 
from the diabetic mouse strain db/db and their non-diabetic controls, db/+ mice. Results 
presented show that HS structures were not different in kidneys from the two mouse strains, 
but a relative decrease in the sulfation of CS could be demonstrated in kidneys from db/db 
mice when compared to db/+ controls. These findings suggest that kidney CS undergoes 
significant changes that should be taken into consideration when appraising the possible 
importance of PG changes in diabetic kidney. 
EXPERIMENTAL PROCEDURES 
Tissue extraction of GAGs and preparation of disaccharides - Kidneys were obtained 
from four db/db diabetic mice and four db/+ non-diabetic heterozygote littermates.  The mean 
body weight was 49.2 g and 27.9 g, respectively, and the animals were 10-12 weeks old when 
sacrificed. The isolation of GAG chains was performed as described by Ledin et al (28). 
Mouse kidney cortexes were dissected from mouse kidneys and external fat was removed. 
The cortexes were freeze homogenized in a Bio-Pulverizer from Research Products 
International Corp and then freeze dried. The freeze dried kidney cortexes differed in mass 
from 20 to 36 mg dry weight and all results were normalized to 30 mg dry weight.
4 parallels (cortex from ½ kidney) from each group of mice (db/db and db/+) were 
degraded with Pronase (0.8 mg/ml; Pronase 165921, Roche Diagnostic)  in 0.5 ml of Pronase 
buffer (50 mM Tris-HCl, pH 8.0, 1 mM CaCl2 and 1% (w/w) Triton X-100) at 55 C 
overnight with shaking. Subsequently, 0.4 mg of Pronase E from Sigma (P5147) was added 
and the samples were incubated for three more hours.  After heat inactivation and adjustment 
to 2 mM MgCl2, 12 mU endonuclease (Benzonase E8263; Sigma) was added, followed by 
additional two hours incubation at 37 °C, heat inactivation, and adjustment to 0.1 M NaCl. 
GAG chains were isolated by ion-exchange chromatography on 0.3 ml DEAE-
Sephacel (GE Healthcare) columns as described in Grøndahl et al (29). Columns were primed 
by washing with 2 M NH4HCO3, followed by loading buffer (50 mM Tris-HCl, pH 8.0, 0.1 M 
NaCl, 0.1 % (w/w) Triton X-100). Samples were applied, and the columns were washed 
successively with loading buffer, pH 8.0, washing buffer, pH 4.0 (50 mM sodium acetate, pH 
4.0, 0.1 M NaCl, 0.1 % (w/w) Triton X-100) and 0.2 M NH4HCO3. GAG chains were eluted 
with 3 x 0.3 ml 2 M NH4HCO3, and collected in micro-centrifuge tubes and repeatedly freeze-
dried until the pH of the samples was close to 7. The samples were dissolved in 50 μl (final 
volume) hyaluronidase (HAdase) buffer (0.05 M Na-phosphate buffer, pH 6.2), added 2.5 mU 
HAdase (100741, Seikagaku) to a final concentration of 0.1 mU/μl HAdase buffer, incubated 
at 37 C for 2.5 hours and inactivated. 10 % of the sample volume was subjected to 
disaccharide analysis. After freeze drying, the samples were dissolved in 50 μl (final volume) 
cABC (chondroitinase ABC)  buffer, pH 8.0, and the whole volume was incubated with 0.2 
mU cABC (100330, Seikagaku)/μl cABC buffer  (33 mM Tris–HCl and 33 mM sodium 
acetate, pH 8.0) for 2.5 hours at 37 °C and inactivated. Yet another 10 % of the original 
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sample volume was subjected to disaccharide analysis. The remaining part of the samples 
were centrifuged with Microcon UM-3 centrifuge filters from Millipore to remove hyaluronan 
(HA) and CS disaccharides before they were divided in two equal parts; one half was 
subjected to disaccharide analysis. The other half was dissolved in 20 μl (final volume) of 
HS-degrading buffer (5 mM HEPES, 2 mM CaCl2, 50 mM NaCl, 0.01 % BSA, pH 7.5) added 
0.6 mU of each of heparinase I, II and III (GE0001, GE0002, GE0003, Grampian Enzymes) 
to a final concentration of 0.03 mU/μl of each of the three heparinases, incubated at 28 °C for 
16 hours, inactivated and subjected to disaccharide analysis.
HPLC disaccharide analysis - Quantitative analysis of disaccharides was performed 
by reverse phase ion pair (RPIP)-HPLC (30) on a Luna 5 C18 reversed phase column (4.6 × 
150 mm, Phenomenex) in acetonitrile (8.5 %) and tetra-n-butylammonium hydrogen sulfate 
(1.2 mM; 86853, Fluka) by applying a stepwise gradient of 0.2 M NaCl from 1 to 62 %. The 
HPLC system (altogether purchased from Dionex) was run at a flow rate of 1.1 ml/minute, 
and the fluorescent labelling reaction was performed by post column addition of 2-
cyanoacetamide (0.25 %; 10.844-8,  Sigma) and NaOH (0.25 %) at a flow rate of 0.35 ml/min 
by a PC10 post-column pneumatic delivery package (Dionex). Signals were quantified by 
comparison with known amounts of standard disaccharides (Sigma and Grampian Enzymes) 
analyzed in parallel runs. The chromatography software used was Chromeleon from Dionex. 
Statistical analysis - The mean number of moles of different disaccharides in diabetic 
and control mice was analyzed for possible statistical differences using an unpaired t-test. P-
values < 0.05 were considered to be statistical significant. P < 0.05 was denoted with * and p 
< 0.005 was denoted with **.
Immunohistochemistry - Immunohistochemistry was performed on 4μm thick sections 
of ZBF-fixed, paraffin embedded kidney tissue from nine db/+ mice and nine db/db mice. 
Sections were deparaffinized in xylene and rehydrated in graded alcohol, followed by 10 
minutes incubation in 3 % hydrogen peroxide to block endogenous peroxidase activity. To 
reduce unspecific staining, sections were incubated with 1.5 % normal goat serum (Dako) in 
PBS for 20 minutes, and antibodies were diluted in the same solution. Sections were then 
incubated with primary monoclonal antibodies against perlecan (Millipore MAB1948P, clone 
A7L6, diluted 1:50) for 60 minutes at room temperature, or with primary polyclonal 
antibodies against collagen IV (Millipore, AB756P, diluted 1:200) for 30 minutes at room 
temperature. Sections stained for perlecan were then incubated with a rabbit anti rat linking 
antibody (Dako, E0468, diluted 1:400) for 30 minutes at room temperature. For all sections 
horseradish peroxidase (HRP)-labeled goat anti rabbit secondary antibodies and 
diaminobenzidine substrate was used for visualization (Dako, EnVision+ system-HRP for 
rabbit primary antibodies) according to product manuals, before counter-staining in Harris 
Heamatoxylin (Chemi - Teknik). All antibody incubation steps were followed by rinsing in 
PBS 3 x 5 minutes. Sections in which the primary antibody was replaced by 1.5 % normal 
goat serum were used as negative controls. 
 
RESULTS
In a previous study on parallel kidney tissue sections from the same db/db mice, 
electron microscopy analyses and morphometric analyses showed that BMs were thicker and 
glomeruli surface areas were expanded compared to corresponding tissue in db/+ mice (31).  
Here, new sections were analyzed for possible difference in HS distribution by using an 
antibody against perlecan, a classical PG in BM. From Fig. 1 upper panel it is evident that 
there is no difference in perlecan staining between kidney sections from db/db and db/+ mice. 
Furthermore, staining with an antibody against the important collagen in BM, collagen IV, did 
not reveal any difference in staining patterns nor intensity between the two tissues examined, 
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neither in glomeruli nor in the tubules (Fig. 1, lower panel). In essence, although the kidneys 
in the db/db mice were shown to be affected using morphometry (31), no differences using 
immunohistochemistry against two prominent BM components could be demonstrated.  
For more detailed analyses of possible differences between kidneys from db/db and 
db/+ mice involving PGs in the kidneys, GAGs were isolated from the glomeruli-rich cortex 
from both animal groups. Based on susceptibility to enzymes degrading either HA, CS/DS or 
HS, the ratio between the different GAGs was not different in material from db/db and db/+ 
mice, as can be seen in Fig. 2. The dominating GAG is HS, representing 74-75 % of the total 
GAG in both preparations, whereas the CS/DS content was 18-20 % and HA approximately 6 
%. Notably, the recovery of total GAGs was similar from both types of kidneys. 
The disaccharide composition of HS was further analyzed by RPIP-HPLC after 
heparinase digestions. The elution of the disaccharides obtained was compared to those of 
defined disaccharide standards. No differences between HS disaccharides from kidneys of 
db/db and db/+ could be detected, which is evident in Fig. 3, showing mean number of moles 
adjusted to 30 mg tissue. From these data it can be calculated that the N-acetylated regions in 
both HS species represent approximately 40 % of the total and the N-sulfated regions 
approximately 60 %, which is typical for several HSPGs, including those in kidney (32). The 
amount of the di- and tri-sulfated disaccharide was similar in both types of material.  
Disaccharides with free glucosamine (GlcN) units could also be detected, but the variation 
between the different samples was so high that no conclusion on possible differences in 
amount of this particular structure could be made. The amount (mean ± SEM) of sulfate per 
disaccharide unit was 0.90 ± 0.03 for HS from db/db mice and 0.79 ± 0.10 for HS from db/+ 
mice, demonstrating that there is no significant difference in sulfation of HS in material from 
diabetic db/db mice compared to db/+ control mice. 
Further analyses were performed to determine the CS/DS structure in the kidney 
material from the two mouse strains.  The disaccharides obtained after cABC treatment were 
also subjected to HPLC analyses. From Fig. 4 it is evident that the major monosulfated 
disaccharide was the 4-O-sulfated species in material from both db/+ and db/db mice. The 
ratio between the 4-O-sulfated and 6-O-sulfated disaccharides was similar in the two groups; 
6.1 in db/+ material and 6.8 in corresponding db/db material.  However, the total amount of 
the two monosulfated disaccharide types was significantly lower in kidney material from the 
diabetic db/db mice, with p = 0.0118 for the 4-O-sulfated D0a4 disaccharide, and p = 0.0022 
for the 6-O-sulfated D0a6 disaccharide. On a molar basis the amount of 4-O-sulfated and 6-
O-sulfated disaccharides in db/db mice was reduced 41 % compared to the db/+ control mice.  
Correspondingly, the amount of unsulfated D0a0 disaccharides was 2.4 times higher in kidney 
cortex from db/db mice compared to db/+ mice. The amount of more highly sulfated 
disaccharides was low in both preparations. The level of disaccharides with 4-and 6-O 
sulfated GalNAc (D0a10) was somewhat higher than disaccharides with sulfate groups in 
position 4 on the GalNAc and position 2 on the uronic acid part (D2a4).  However, there was 
no difference in the amount of these disaccharides in kidney extracts from the two different 
mouse strains. The percent distribution of the different disaccharides is shown in Table1. 
From these analyses on CS in the kidney extracts it can be concluded that kidneys from the 
diabetic db/db mice contain CS with a lower degree of sulfation than db/+ control mice. The 
difference in sulfation is summarized in Fig. 5 and clearly demonstrates that the sulfation of 
CS, but not HS, is significantly reduced in kidney PGs from db/db mice compared to db/+ 
mice (p = 0.0036).  
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DISCUSSION 
The db/db mouse is a well-suited animal model for type 2 diabetes with renal diseases, 
and can be used to study diabetic nephropathy (33). In the present study we have used kidneys 
from these animals and corresponding db/+ controls for immunohistochemical and GAG 
structure analyses.  The immunohistochemical analyses did not reveal any differences in 
neither perlecan nor collagen IV staining between tissues from the two animal groups. In 
another study on parallel tissues to those used here increased BM thickness and expanded 
glomerular surface areas in kidneys of db/db mice compared to db/+ mice was demonstrated 
(31),  clearly showing that the kidneys of the db/db mice used here are affected. The two latter 
analyses were done using electron microscopy giving more detailed data than 
immunohistochemistry used in this study.  
In the present study, we found no difference in the total GAG amount between the 
normal and the diabetic kidney. Also, the data we present on the structures of kidney HS did 
not reveal any differences in disaccharide compositions between preparations from db/db and 
db/+ mice. The major fraction of the disaccharides contained GlcN units that were either N-
sulfated or N-acetylated. Our HS disaccharide analyses are in line with those presented 
recently for liver HS in mice made diabetic by streptozotocin injection (24). Although our 
analyses concerned a different tissue, it is interesting to note that HS changes were not 
detected in neither liver nor kidney, two organs affected in insulin dependent diabetic mice 
(type 1 diabetes) and mice used as a model for type 2 diabetes. Also, in rats made diabetic 
with streptozotocin, glomerular HS structure was not altered (25), while in a similar study, 
kidney HS from large glomeruli was less N-sulfated than HS from controls (26).  Also, an 
early study on livers from diabetic rats showed decreased sulfation of HS (22). Whether there 
is a difference in the changes observed for HS in diabetic rats compared to diabetic mice has, 
however, not been reported. Such comparative analysis would be interesting, as it is not a 
trivial issue which animal model is best suited for studies on diabetes, both for studies on its 
development and pathology and treatment and search for early disease and tissue 
complication markers.   
The major results in the present study are the changes we observe in kidney CS 
structures. The major disaccharide components of CS GAGs in control kidney preparations 
were D0a4 (CS-4) constituting 65 % and D0a0 (C-0S) which amounted to 21.5 % of the total 
CS disaccharides. In kidneys of db/db mice D0a4 disaccharides was reduced to 40 % and the 
non-sulfated species increased to 51 % of the total of disaccharides.  To the best of our 
knowledge, such changes in CS structures in kidneys of diabetic mice have not been reported 
before. One recent report, did demonstrate structural changes in CS/DS in rat kidney, but 
these were due to a decrease in the percentage of disaccharides of the oversulfated D0a10 
type. The degree of CS/DS sulfation was only slightly reduced (27).  
The functional implications of the CS structural changes in mouse diabetic kidney 
reported here remains to be established.  It is interesting to note that the biological functions 
of kidney HS linked to filtration are still a matter of debate (11-13).  There has been little 
focus so far on the possible importance of kidney CS/DS for filtration or other kidney 
functions. One probable reason for this is that CS/DS represent a much smaller part of the 
total kidney GAGs than HS and has therefore been regarded as less important.  In the kidneys 
studied here, HS and CS represented approximately 75 and 17 %, respectively of total kidney 
GAG.  However, the large decrease we found in CS sulfation could potentially affect the 
functions of kidney PGs carrying CS chains.  
In the diabetic kidney, changes in CS/DS PGs like decorin and biglycan have been 
reported (34).  Furthermore, both mRNA and protein expression of the transmembrane CSPG 
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NG2 increased in kidneys of diabetic rats (35). Decorin, biglycan and NG2 functions can 
potentially be changed if the sulfation of their CS/DS chains is decreased, as demonstrated 
here for the total kidney CS. Furthermore, immunoelectron microscopy with an antibody 
against a CSPG core protein showed increased staining of BM of diabetic rat kidneys, in 
particularly in areas where BM thickening was evident (36). If such a BM CSPG is important 
for filtration in the kidneys, the findings we report here may have relevance to changes in this 
function in diabetes. 
CS/DS in the endothelial glycocalyx may also be relevant to the structural changes we 
report, as the removal of these GAGs affects glomerular filtration (18). A lowered charge in 
the glycocalyx could affect filtration functions. Accordingly, there are several CSPGs that 
have important kidney functions, and changes in the sulfation of their respective GAG chains 
could possibly affect such functions. 
CS/DS PGs in the kidneys are located both in the BM, the mesangium, the 
tubulointerstitial space and the glycocalyx (1).  The results presented show that the sulfation 
of CS in kidneys is reduced in db/db diabetic mice. It has been documented that this is a good 
animal model for type 2 diabetes in humans. Our study raises new questions on the functions 
of PGs in the kidneys and for CSPGs in diabetes in particular.  In future studies it will be of 
interest to investigate whether the reported CS/DS changes in mice are also evident in kidney 
biopsies in persons with type 1 and type 2 diabetes. 
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Disaccharide notations used for HS: D0H0 = UA-GlcNH2, D0A0 = UA-GlcNAc, D0S0 = 
UA-GlcNS, D0A6 = UA-GlcNAc6S, D0S6 = UA-GlcNS6S, D2S0 = UA2S-GlcNS, 
D2A6 = UA2S-GlcNAc6S and D2S6 = UA2S-GlcNS6S. Disaccharide notations used for 
CS: D0a0 = UA-GalNAc, D0a4 = UA-GalNAc4S, D0a6 = UA-GalNAc6S, D0a10 = 
UA-GalNAc4S6S, D2a4 = UA2S-GalNAc4S 
 
 
FIGURE LEGENDS 
 
FIGURE 1. Immunohistochemistry of diabetic and control mouse kidney. Kidney 
sections from diabetic (db/db) mice and control (db/+) mice were subjected to 
immunohistochemistry using antibodies against perlecan (upper panels) and collagen IV 
(lower panels). Magnification is 400x, and the results are representative of analysis on nine 
mice from each group.
FIGURE 2. Relative distribution of HA, CS/DS and HS in kidney from diabetic and 
control mice. The disaccharide composition of GAGs from four diabetic (db/db) and four 
control (db/+) mice were analyzed after subjected to enzymatic degradation of HA, CS/DS or 
HS respectively. The results are presented as mean percent of total moles, with standard error 
indicated by vertical bars.  
FIGURE 3. HS disaccharide structure in diabetic and control mouse kidney. HS 
disaccharide structures were analyzed by RPIP HPLC following heparinase digestion. The 
elution time of the disaccharides was compared to those of defined disaccharide standards. 
The notation is as follows (37): D0H0 = UA-GlcNH2, D0A0 = UA-GlcNAc, D0S0 = 
UA-GlcNS, D0A6 = UA-GlcNAc6S, D0S6 = UA-GlcNS6S, D2S0 = UA2S-GlcNS, 
D2A6 = UA2S-GlcNAc6S and D2S6 = UA2S-GlcNS6S. The results are presented as 
mean moles adjusted to 30 mg tissue in each sample, with standard error indicated by vertical 
bars.  Statistical significance of differences between four db/+ and four db/db mice were 
tested using the students t-test, and no significant differences were found. 
FIGURE 4. CS disaccharide structure in diabetic and control mouse kidney. CS/DS 
disaccharide structures were analyzed by RPIP HPLC following cABC digestion. The elution 
time of the disaccharides was compared to those of defined disaccharide standards. The 
notation is as follows (37): D0a0 = UA-GalNAc, D0a4 = UA-GalNAc4S, D0a6 = UA-
GalNAc6S, D0a10 = UA-GalNAc4S6S, D2a4 = UA2S-GalNAc4S. The results are 
presented as mean moles, adjusted to 30 mg tissue in each sample, with standard error 
indicated by vertical bars. Statistical significance of differences between the four db/+ and 
four db/db mice were tested using the students t-test, * denotes p < 0.05 and ** denotes p < 
0.005. 
FIGURE 5. Degree of sulfation of CS/DS and HS in diabetic and control mouse kidney. 
The number of sulfates per disaccharide was determined for both HS and CS/DS and 
presented as mean and SEM. The statistical significance of the difference between four db/db 
mice and four db/+ mice was tested using the students t-test, a p value < 0.005 is denoted by 
**. 
TABLES
TABLE 1 Mean % distribution of the different CS/DS disaccharides with SEM 
 D0a0 D0a4 D0a6 D0a10 D2a4 
db/+ 21.52 ± 2.47 65.06 ± 1.72 10.77 ± 0.67 2.06 ± 0.21 0.60 ± 0.08 
Chondroitinsulfateindiabetickidney
db/db 51.10 ± 5.90 40.23 ± 4.88   6.21 ± 1.08 2.06 ± 0.09 0.39 ± 0.05 
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Errata 
Please note the following corrections to the thesis: 
 
Paper IV 
 
Footnotes  
Disaccharide notations used for HS:  
“….D0A0 = ∆UA-GlcNAc, D0S0 = ……..” should read  
“….D0A0 = ∆UA-GlcNAc, D0A2 = ∆UA2S-GlcNAc, D0S0 = ……..” 
 
Figure legends 
FIGURE 3 
“….D0A0 = ∆UA-GlcNAc, D0S0 = ……..” should read  
“….D0A0 = ∆UA-GlcNAc, D0A2 = ∆UA2S-GlcNAc, D0S0 = ……..” 
 
Fig 3 
The notation “D0A2” is miss-spelled; it should read “D2A0” 

